

## **PRODUCT MONOGRAPH**

**Pr TARO-DESVENLAFAXINE**

desvenlafaxine extended-release tablets

50 mg and 100 mg desvenlafaxine (as desvenlafaxine succinate monohydrate)

Antidepressant

Taro Pharmaceuticals Inc.  
130 East Drive  
Brampton, Ontario  
L6T 1C1

Date of Revision:  
OCT 19, 2022

Submission Control No.: 264187

## Table of Contents

<b>PART I: HEALTH PROFESSIONAL INFORMATION.....</b>	<b>3</b>
SUMMARY PRODUCT INFORMATION .....	3
INDICATIONS AND CLINICAL USE.....	3
CONTRAINDICATIONS .....	4
WARNINGS AND PRECAUTIONS .....	4
ADVERSE REACTIONS .....	11
DRUG INTERACTIONS.....	21
DOSAGE AND ADMINISTRATION.....	24
OVERDOSAGE .....	27
ACTION AND CLINICAL PHARMACOLOGY .....	28
STORAGE AND STABILITY .....	31
SPECIAL HANDLING INSTRUCTIONS .....	31
DOSAGE FORMS, COMPOSITION AND PACKAGING .....	31
<b>PART II: SCIENTIFIC INFORMATION.....</b>	<b>33</b>
PHARMACEUTICAL INFORMATION .....	33
CLINICAL TRIALS .....	34
DETAILED PHARMACOLOGY.....	39
TOXICOLOGY .....	42
REFERENCES .....	46
<b>PART III: CONSUMER INFORMATION .....</b>	<b>47</b>

Pr  
**TARO-DESVENLAFAXINE**

desvenlafaxine extended-release tablets  
50 and 100 mg desvenlafaxine as desvenlafaxine succinate monohydrate

## **PART I: HEALTH PROFESSIONAL INFORMATION**

### **SUMMARY PRODUCT INFORMATION**

<b>Route of Administration</b>	<b>Dosage Form / Strength</b>	<b>Nonmedicinal Ingredients</b>
Oral	extended-release tablet / 50 mg, and 100 mg desvenlafaxine (as desvenlafaxine succinate monohydrate)	hypromellose, hydroxyethyl cellulose, ethyl cellulose, microcrystalline cellulose, magnesium stearate, film coating (which consists of polyvinyl alcohol, titanium dioxide, polyethylene glycol, talc, red iron oxide, black iron oxide (50 mg only), yellow iron oxide (100 mg only))

### **INDICATIONS AND CLINICAL USE**

#### **Adults**

**Taro-Desvenlafaxine** (desvenlafaxine extended-release tablets) is indicated for the symptomatic relief of major depressive disorder.

The short-term efficacy of desvenlafaxine extended-release tablets has been demonstrated in placebo-controlled trials of up to 8 weeks.

The efficacy of desvenlafaxine extended-release tablets in maintaining an antidepressant response for up to 26 weeks, following response during 20 weeks of acute, open-label treatment, was demonstrated in a placebo-controlled trial.

#### **Pediatrics (< 18 years of age)**

Based on the data submitted and reviewed by Health Canada, the safety and efficacy of **Taro-Desvenlafaxine** in pediatric patients have not been established; therefore, Health Canada has not authorized an indication for pediatric use.

Two placebo controlled studies in 587 pediatric patients 7 to 17 years of age with MDD failed to demonstrate efficacy; neither short term, placebo-controlled study demonstrated statistically or clinically significant differences between desvenlafaxine extended-release tablets and placebo (see

**WARNINGS AND PRECAUTIONS**, Potential Association with Behavioural and Emotional Changes, Including Self-Harm; also Special Populations, Pediatrics; **ADVERSE REACTIONS**, Pediatrics **ACTION AND CLINICAL PHARMACOLOGY**, Pediatrics).

## CONTRAINDICATIONS

- **Taro-Desvenlafaxine** must not be used concomitantly in patients taking monoamine oxidase inhibitors (MAOIs), including linezolid, an antibiotic, methylene blue, a dye used in certain surgeries, or in patients who have taken MAOIs within the preceding 14 days due to the risk of serious, sometimes fatal, drug interactions with selective serotonin reuptake inhibitor (SSRI) or serotonin norepinephrine reuptake inhibitor (SNRI) treatment or with other serotonergic drugs. These interactions have been associated with symptoms that include tremor, myoclonus, diaphoresis, nausea, vomiting, flushing, dizziness, hyperthermia with features resembling neuroleptic malignant syndrome, seizures, rigidity, autonomic instability with possible rapid fluctuations of vital signs, and mental status changes that include extreme agitation progressing to delirium and coma. Based on the half-life of desvenlafaxine succinate, at least 7 days should be allowed after stopping desvenlafaxine succinate and before starting an MAOI.
- Hypersensitivity to desvenlafaxine extended-release tablets, venlafaxine hydrochloride or to any excipients in the desvenlafaxine formulation (see **DOSAGE FORMS, COMPOSITION AND PACKAGING**).

## WARNINGS AND PRECAUTIONS

### POTENTIAL ASSOCIATION WITH BEHAVIOURAL AND EMOTIONAL CHANGES, INCLUDING SELF-HARM.

#### **Pediatrics: Placebo-Controlled Clinical Trial Data**

Recent analyses of placebo-controlled clinical trial safety databases from Selective Serotonin Reuptake Inhibitors (SSRIs) and other newer anti-depressants suggest that use of these drugs in patients under the age of 18 may be associated with behavioural and emotional changes, including an increased risk of suicidal ideation and behaviour over that of placebo.

The small denominators in the clinical trial database, as well as the variability in placebo rates, preclude reliable conclusions on the relative safety profiles among the drugs in the class.

Taro-Desvenlafaxine is not indicated for use in pediatric patients (see **INDICATIONS**).

#### **Adults and Pediatrics: Additional data**

There are clinical trial and post-marketing reports with SSRIs and other newer antidepressants, in both pediatrics and adults, of severe agitation-type adverse events coupled with self-harm or harm to others. The agitation-type events include: akathisia, agitation, disinhibition, emotional lability, hostility, aggression, and depersonalization. In some cases, the events occurred within several weeks of starting treatment. Rigorous clinical monitoring

for suicidal ideation or other indicators of potential for suicidal behaviour is advised in patients of all ages especially when initiating therapy or during any change in dose or dosage regimen. This includes monitoring for agitation-type emotional and behavioural changes.

An FDA meta-analysis of placebo-controlled clinical trials of antidepressant drugs in adult patients ages 18 to 24 years with psychiatric disorders showed an increased risk of suicidal behaviour with antidepressants compared to placebo.

### **Aggression**

Aggression may occur in some patients who have received antidepressants, including desvenlafaxine treatment, dose reduction, or discontinuation. As with other antidepressants, desvenlafaxine should be used cautiously in patients with a history of aggression.

### **Discontinuation**

Discontinuation effects are well known to occur with antidepressants, and sometimes these effects can be protracted and severe (see [ADVERSE REACTIONS](#)). Suicide/suicidal thoughts and aggression have been observed in patients during changes in desvenlafaxine dosing regimen, including during discontinuation (see [WARNINGS AND PRECAUTIONS, Discontinuation Effects](#)). It is therefore recommended that the dosage of desvenlafaxine be tapered gradually and individually and the patients be closely monitored during discontinuation (see [DOSAGE AND ADMINISTRATION](#)). In some patients, discontinuation could take months or longer.

### **Sexual Dysfunction**

Serotonin-norepinephrine reuptake inhibitors (SNRIs) may cause symptoms of sexual dysfunction (see [ADVERSE REACTIONS](#)). There have been reports of long-lasting sexual dysfunction where the symptoms have continued despite discontinuation of SNRIs.

### **General**

#### **Concomitant Use of Taro-Desvenlafaxine with VENLAFAXINE**

Since desvenlafaxine is the major active metabolite of venlafaxine, concomitant use of **Taro-Desvenlafaxine** with products containing Venlafaxine is not recommended since the combination of the two will lead to additive desvenlafaxine exposure.

#### **Allergic Reactions**

Patients should be advised to notify their physician if they develop a rash, hives or a related allergic phenomenon.

#### **Bone Fracture Risk**

Epidemiological studies show an increased risk of bone fractures following exposure to some antidepressants, including SSRIs/SNRIs. The risks appear to be greater at the initial stages of treatment, but significant increased risks were also observed at later stages of treatment. The possibility of fracture should be considered in the care of patients treated with **Taro-Desvenlafaxine**. Elderly patients and patients with important risk factors for bone fractures should be advised of possible adverse events which increase the risk of falls, such as dizziness and

orthostatic hypotension, especially at the early stages of treatment but also soon after withdrawal. Preliminary data from observational studies show association of SSRIs/SNRIs and low bone mineral density in older men and women. Until further information becomes available, a possible effect on bone mineral density with long term treatment with SSRIs/SNRIs, including **Taro-Desvenlafaxine**, cannot be excluded, and may be a potential concern for patients with osteoporosis or major risk factors for bone fractures.

### **Carcinogenesis and Mutagenesis**

For animal data see **TOXICOLOGY**.

### **Cardiovascular/Cerebrovascular**

Caution is advised in administering **Taro-Desvenlafaxine** to patients with cardiovascular, cerebrovascular, or lipid metabolism disorders (see **Clinical Trial Adverse Drug Reactions**). Increases in blood pressure and heart rate were observed in clinical trials with desvenlafaxine extended-release tablets. Desvenlafaxine extended-release tablets have not been evaluated systematically in patients with a recent history of myocardial infarction, unstable heart disease, uncontrolled hypertension, or cerebrovascular disease. Patients with these diagnoses, except for cerebrovascular disease, were excluded from clinical trials.

#### ***Effects on blood pressure***

Cases of elevated blood pressure requiring immediate treatment have been reported with desvenlafaxine in post marketing experience, including reports of hypertensive crisis and malignant hypertension. Increases in blood pressure were observed in some patients in clinical trials, particularly with higher doses. Caution should be exercised in treating patients with underlying conditions that might be compromised by increases in blood pressure (see **ADVERSE REACTIONS, Vital Sign Changes**). Pre-existing hypertension should be controlled before treatment with **Taro-Desvenlafaxine**. Patients receiving **Taro-Desvenlafaxine** should have regular monitoring of blood pressure. Sustained blood pressure increases could have adverse consequences. For patients who experience a sustained increase in blood pressure while receiving **Taro-Desvenlafaxine**, either dose reduction or discontinuation should be considered.

Treatment with desvenlafaxine extended-release tablets at all doses from 50 mg/day to 400 mg/day in controlled studies was associated with sustained hypertension (defined as treatment-emergent supine diastolic blood pressure  $\geq 90$  mm Hg and  $\geq 10$  mm Hg above baseline for 3 consecutive visits). Table 1 provides the incidence of patients meeting criteria for sustained hypertension.

**Table 1: Incidence (%) of Patients with Sustained Hypertension for All Short-Term Fixed-Dose Clinical Trials**

	Placebo	----- Desvenlafaxine extended-release tablets-----			
		50 mg	100 mg	200 mg	400 mg
<b>Sustained hypertension</b>	0.5	1.3	0.7	1.1	2.3

### **Dependence/Tolerance**

Although desvenlafaxine succinate has not been systematically studied in preclinical or clinical trials for its potential for abuse, no indication of drug-seeking behavior was seen in the clinical trials.

## Discontinuation Symptoms

At the time that a medical decision is made to discontinue **Taro-Desvenlafaxine**, a gradual reduction in the dose, rather than an abrupt cessation, is recommended.

During marketing of SNRIs, and SSRIs, there have been post-marketing reports of adverse events occurring upon discontinuation of these drugs, particularly when abrupt, including the following: dysphoric mood, irritability, agitation, dizziness, sensory disturbances (e.g., paraesthesias, such as electric shock sensations), anxiety, confusion, headache, lethargy, emotional lability, insomnia, hypomania, tinnitus, seizures, visual impairment and hypertension. While these events are generally self-limiting, there have been reports of serious discontinuation symptoms. In addition, suicide/suicidal thoughts and aggression have been observed in patients during changes in desvenlafaxine dosing regimen, including during discontinuation.

Patients should be monitored for these symptoms when discontinuing treatment with **Taro-Desvenlafaxine**. A gradual reduction in the dose rather than abrupt cessation is recommended whenever possible. If intolerable symptoms occur following a decrease in the dose or upon discontinuation of treatment, then resuming the previously prescribed dose may be considered. Subsequently, the physician may continue decreasing the dose but at a more gradual rate (see **ADVERSE REACTIONS, Discontinuation Symptoms, and DOSAGE AND ADMINISTRATION, Discontinuing Taro-Desvenlafaxine**). In some patients, discontinuation may need to occur over periods of months or longer.

## Endocrine and Metabolism

### *Serum Cholesterol Elevation*

Increases in cholesterol (total and LDL) and triglycerides were observed in some patients treated with desvenlafaxine succinate in placebo-controlled pre-marketing clinical trials, particularly with higher doses. Measurement of serum lipid levels should be considered during treatment.

### *Hyponatremia*

Cases of hyponatremia and/or the Syndrome of Inappropriate Antidiuretic Hormone (SIADH) secretion have been described with SNRIs and SSRIs, usually in volume-depleted or dehydrated patients, including elderly patients and patients taking diuretics.

## Gastrointestinal

### *Potential for Gastrointestinal Obstruction*

Because the **Taro-Desvenlafaxine** tablet does not appreciably change in shape in the gastrointestinal tract, **Taro-Desvenlafaxine** should not be administered to patients with pre-existing gastrointestinal narrowing (pathologic or iatrogenic, such as small bowel inflammatory disease, “short gut” syndrome due to adhesions or decreased transit time, past history of peritonitis, cystic fibrosis, chronic intestinal pseudo-obstruction, or Meckel’s diverticulum). There have been rare reports of obstructive symptoms in patients with known strictures in association with the ingestion of other drugs in nondeformable controlled-release formulations, and very rare reports of obstructive symptoms associated with the use of nondeformable controlled-release formulations in patients without known gastrointestinal stricture. Due to the controlled-release design, **Taro-**

**Desvenlafaxine** tablets should only be used in patients who are able to swallow the tablets whole. (See **DOSAGE AND ADMINISTRATION; Recommended Dose and Dosage Adjustment**).

## **Hematologic**

### ***Abnormal Bleeding***

SSRIs and SNRIs, including **Taro-Desvenlafaxine**, may increase the risk of bleeding events by causing abnormal platelet aggregation. Concomitant use of acetylsalicylic acid (ASA), nonsteroidal anti-inflammatory drugs (NSAIDs), warfarin and other anticoagulants may add to the risk. Case reports and epidemiological studies (case-control and cohort design) have demonstrated an association between use of drugs that interfere with serotonin reuptake and the occurrence of gastrointestinal bleeding. Bleeding events related to SSRIs and SNRIs use have ranged from ecchymoses, hematomas, epistaxis, and petechiae to life-threatening hemorrhages. Patients should be cautioned about the risk of bleeding associated with the concomitant use of **Taro-Desvenlafaxine** and NSAIDs, ASA, or other drugs that affect coagulation (see **DRUG INTERACTIONS, Drugs Affecting Platelet Function**). Caution is advised in patients with a history of bleeding disorder or predisposing conditions (e.g., thrombocytopenia).

### **Interstitial Lung Disease and Eosinophilic Pneumonia**

Interstitial lung disease and eosinophilic pneumonia associated with venlafaxine (the parent drug of desvenlafaxine) therapy have been rarely reported. The possibility of these adverse events should be considered in patients treated with **Taro-Desvenlafaxine** who present with progressive dyspnea, cough, or chest discomfort. Such patients should undergo a prompt medical evaluation, and discontinuation of **Taro-Desvenlafaxine** should be considered.

## **Neurologic**

### ***Seizures***

Cases of seizures have been reported in trials with desvenlafaxine extended-release tablets. Desvenlafaxine succinate should be prescribed with caution in patients with a seizure disorder. Desvenlafaxine has not been systematically evaluated in patients with a seizure disorder.

### ***Serotonin Syndrome or Neuroleptic Malignant Syndrome (NMS)-Like Reactions***

As with other serotonergic agents, serotonin syndrome or Neuroleptic Malignant Syndrome (NMS)-like reactions, a potentially life-threatening condition, have been reported with SNRIs and SSRIs alone, including **Taro-Desvenlafaxine** treatment, particularly with concomitant use of other agents that may affect the serotonergic neurotransmitter systems (such as amphetamines, triptans, serotonin reuptake inhibitors, sibutramine, MAOIs (including linezolid, an antibiotic, and methylene blue), St. John's Wort (*Hypericum perforatum*) and/or lithium) and with drugs that impair metabolism of serotonin or with antipsychotics or other dopamine antagonists. Serotonin syndrome symptoms may include mental status changes (e.g., agitation, hallucinations, and coma), autonomic instability (e.g., tachycardia, labile blood pressure, and hyperthermia), neuromuscular aberrations (e.g., hyperreflexia, incoordination) and/or gastrointestinal symptoms (e.g., nausea, vomiting, and diarrhea). Serotonin syndrome, in its most severe form, can resemble NMS, which includes hyperthermia, muscle rigidity, autonomic instability with possible rapid fluctuation of vital signs, and mental status changes.



If concomitant treatment with desvenlafaxine and other agents that may affect the serotonergic and/or dopaminergic neurotransmitter system (such as another SSRI/SNRI) or a 5-hydroxytryptamine receptor agonist (triptan) is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases. The concomitant use of desvenlafaxine with serotonin precursors (such as tryptophan supplements) is not recommended (see **DRUG INTERACTIONS, Serotonin Syndrome**).

Treatment with **Taro-Desvenlafaxine** and any concomitant serotonergic or antidopaminergic agents, including antipsychotics, should be discontinued immediately if the above events occur and supportive symptomatic treatment should be initiated.

## **Ophthalmologic**

### ***Angle-Closure Glaucoma***

As with other antidepressants, **Taro-Desvenlafaxine** can cause mydriasis, which may trigger an angle-closure attack in a patient with anatomically narrow ocular angles. Healthcare providers should inform patients to seek immediate medical assistance if they experience eye pain, changes in vision or swelling or redness in or around the eye.

## **Psychiatric**

### ***Mania/hypomania***

Mania/hypomania may occur in a small proportion of patients with mood disorders who have received medication to treat depression, including desvenlafaxine succinate. During clinical studies, mania and hypomania were reported in approximately 0.15% (12/8,453) of patients treated with desvenlafaxine extended-release tablets. Activation of mania/hypomania has also been reported in a small proportion of patients with major affective disorder who were treated with other marketed antidepressants. As with all antidepressants, **Taro-Desvenlafaxine** should be used cautiously in patients with a history or family history of mania or hypomania.

A major depressive episode may be the initial presentation of bipolar disorder. Patients with bipolar disorder may be at an increased risk of experiencing manic episodes when treated with antidepressants alone. Therefore, the decision to initiate symptomatic treatment of depression should only be made after patients have been adequately assessed to determine if they are at risk for bipolar disorder.

## **Special Populations**

### ***Pregnant Women***

The safety of desvenlafaxine in human pregnancy has not been established. Studies have demonstrated that desvenlafaxine crosses the human placenta. The extent of exposure to desvenlafaxine extended-release tablets in pregnancy during clinical trials was very limited. There are no adequate and well-controlled studies in pregnant women. Therefore, desvenlafaxine should be used during pregnancy only if the potential benefits justify the potential risks. If desvenlafaxine succinate is used until or shortly before birth, discontinuation effects in the newborn should be considered.

Post-marketing reports indicate that some neonates exposed to SNRIs, SSRIs, or other newer

antidepressants late in the third trimester have developed complications requiring prolonged hospitalization, respiratory support, and tube feeding. Such complications can arise immediately upon delivery. Reported clinical findings have included respiratory distress, cyanosis, apnea, seizures, temperature instability, feeding difficulty, vomiting, hypoglycemia, hypotonia, hypertonia, hyper-reflexia, tremor, jitteriness, irritability, and constant crying. These features are consistent with either a direct toxic effect of SNRIs, SSRIs and other newer antidepressants, or, possibly a drug discontinuation syndrome. It should be noted that, in some cases, the clinical picture is consistent with serotonin syndrome (see **DRUG INTERACTIONS**). When treating a pregnant woman with **Taro-Desvenlafaxine** during the third trimester, the physician should carefully consider the potential risks and benefits of treatment.

Any changes in antidepressants medication (including dosage) during pregnancy should be discussed with the attending physician beforehand to discuss the benefits/risks with the patient.

Exposure to SNRIs in mid to late pregnancy may increase the risk for preeclampsia, and exposure to SNRIs near delivery may increase the risk for postpartum hemorrhage.

Patients should be advised to notify their physician if they become pregnant or intend to become pregnant during therapy.

### ***Labour and Delivery***

The effect of desvenlafaxine on labour and delivery in humans is unknown. **Taro-Desvenlafaxine** should be used during labour and delivery only if the potential benefits justify the potential risks.

### ***Nursing Women***

Desvenlafaxine (O-desmethylvenlafaxine, a metabolite of desvenlafaxine) is excreted in human milk. The effects in infants have not been established. **Taro-Desvenlafaxine** should only be taken by breastfeeding women if the expected benefits outweigh any possible risk.

### ***Pediatric***

Based on the data submitted and reviewed by Health Canada, the safety and efficacy of **Taro-Desvenlafaxine** in pediatric patients has not been established; therefore, Health Canada has not authorized an indication for pediatric use (see **WARNINGS AND PRECAUTIONS**, Potential Association with Behavioural and Emotional Changes, Including Self-Harm).

Two placebo controlled studies in 587 pediatric patients 7 to 17 years of age with MDD failed to demonstrate efficacy; neither short term, placebo-controlled study demonstrated statistically or clinically significant differences between desvenlafaxine extended-release tablets and placebo (see **ACTION AND CLINICAL PHARMACOLOGY**, Pediatrics).

The long-term safety, including effects on growth, maturation, and behavioural development, in patients under 18 years of age has not been systemically evaluated. (See **ADVERSE REACTIONS**, Adverse Drug Reactions in Pediatrics).

### ***Geriatrics (≥ 65 years of age)***

Of the 4,158 patients in clinical trials with desvenlafaxine extended-release tablets, 6% were 65 years

of age or older. No overall differences in safety or efficacy were detected between these subjects and younger subjects. However, there was a higher incidence of increases in systolic blood pressure in patients  $\geq 65$  years of age compared to patients  $< 65$  years of age treated with desvenlafaxine extended-release tablets. In addition, there was a higher incidence of systolic orthostatic hypotension in patients  $\geq 65$  years of age compared to all adults treated with desvenlafaxine. For elderly patients, possible reduced renal clearance of desvenlafaxine should be considered when determining dose (see [Dosing Considerations](#), [Geriatrics](#) and [ACTION AND CLINICAL PHARMACOLOGY, Geriatrics](#)). Greater sensitivity of some older individuals cannot be ruled out.

## **Monitoring and Laboratory Tests**

### ***Serum Lipids***

Increases in cholesterol (total and LDL) and triglycerides were observed in some patients treated with desvenlafaxine succinate in placebo-controlled pre-marketing clinical trials, particularly with higher doses. Measurement of serum lipid levels should be considered during treatment.

### ***Heart Rate and Blood Pressure***

Increases in heart rate and blood pressure were observed in some patients in clinical trials, particularly with higher doses. Measurement of blood pressure is recommended prior to initiating treatment and regularly during treatment with desvenlafaxine succinate (see [ADVERSE REACTIONS, Vital Sign Changes](#)).

### ***Self-Harm***

Rigorous clinical monitoring for suicidal ideation or other indicators of potential for suicidal behaviour is advised in patients of all ages. Patients, their families, and their caregivers should be encouraged to be alert to the emergence of anxiety, agitation, panic attacks, insomnia, irritability, hostility, aggressiveness, impulsivity, akathisia (psychomotor restlessness), hypomania, mania, other unusual changes in behavior, worsening of depression, and suicidal ideation, especially when initiating therapy or during any change in dose or dosage regimen. (See [WARNINGS AND PRECAUTIONS, POTENTIAL ASSOCIATION WITH BEHAVIOURAL AND EMOTIONAL CHANGES, INCLUDING SELF-HARM](#)).

## **ADVERSE REACTIONS**

### **Adverse Drug Reaction Overview**

The safety of desvenlafaxine extended-release tablets in major depressive disorder was evaluated in 8,453 patients exposed to at least one dose of desvenlafaxine extended-release tablets.

The most commonly observed treatment emergent adverse events (all-causality) (incidence of 5% or greater for the desvenlafaxine extended-release tablets pooled 50- to 400-mg doses, and incidence higher than placebo) in desvenlafaxine extended-release tablet treated MDD patients in clinical trials were: nausea, headache, dry mouth, dizziness, insomnia, hyperhidrosis, constipation, diarrhea, somnolence, fatigue, decreased appetite, vomiting, and blood pressure increased, and, in men, and erectile dysfunction.

### ***Adverse Events Reported as Reasons for Discontinuation of Treatment in MDD Clinical Trials***

In the 8-week placebo-controlled, pre-marketing trials for MDD, 12% of the 1,834 patients who received desvenlafaxine extended-release tablets (50-400 mg/day) discontinued treatment due to an adverse experience, compared with 3% of the 1,116 placebo-treated patients in those trials.

At the recommended dose of 50 mg, the discontinuation rate due to an adverse experience for desvenlafaxine extended-release tablets (4.1%) was similar to the rate for placebo (3.8%) and only 1% of patients discontinued due to nausea.

The most common adverse reactions leading to discontinuation (i.e., leading to discontinuation in at least 2% and incidence higher than placebo) of the desvenlafaxine extended-release tablet-treated patients in short-term trials of up to 8 weeks were: nausea (4%); dizziness, headache and vomiting (2% each).

### **Clinical Trial Adverse Drug Reactions**

*Because clinical trials are conducted under very specific conditions the adverse reaction rates observed in the clinical trials may not reflect the rates observed in practice and should not be compared to the rates in the clinical trials of another drug. Adverse drug reaction information from clinical trials is useful for identifying drug-related adverse events and for approximating rates.*

### **Adverse Reactions in MDD Clinical Trials**

Desvenlafaxine extended-release tablets were evaluated for safety in 8,453 patients diagnosed with major depressive disorder who participated in multiple-dose trials, representing 2,807 patient-years of exposure. Among these 8,453 desvenlafaxine extended-release tablets-treated patients, 2,495 patients participated in 8-week, placebo-controlled trials at doses ranging from 50 to 400 mg/day. Of the total 8,453 subjects exposed to at least 1 dose of desvenlafaxine extended-release tablets, 2,140 were exposed to desvenlafaxine extended-release tablets for greater than 6 months and 521 were exposed for 1 year.

### **Premarket Clinical Trials**

#### **Treatment-Emergent Adverse Events Occurring at an Incidence of $\geq 2\%$ Among desvenlafaxine extended-release tablet-treated Patients in Short-Term Placebo-controlled Trials**

Table 2 lists alphabetically by body system, the treatment-emergent adverse events that occurred with an incidence  $\geq 2\%$  and greater than placebo (pooled 8-week placebo-controlled, premarket clinical trials).

Reported treatment emergent adverse events were classified using a standard MedDRA-based Dictionary terminology.

**Table 2: Treatment Emergent Adverse Events ( $\geq 2\%$  in Any Desvenlafaxine extended-release tablet Group and More Frequent than Placebo): Percentage of Subjects in Short-Term, Placebo-Controlled MDD Studies**

System Organ Class Preferred Term	Percentage of Patients Reporting Reaction				
	Placebo (n=636)	Desvenlafaxine extended-release tablets			
		50 mg (n=317)	100 mg (n=424)	200 mg (n=307)	400 mg (n=317)
<b>Cardiac disorders</b>					
Palpitations	2	1	3	2	3
Tachycardia	1	1	<1	1	2
<b>Ear and labyrinth disorders</b>					
Tinnitus	1	2	1	1	2
Vertigo	1	2	1	5	3
<b>Eye disorders</b>					
Eye pain	<1	1	2	<1	<1
Mydriasis	<1	2	2	6	6
Vision blurred	1	3	4	4	4
<b>Gastrointestinal disorders</b>					
Abdominal Pain	2	4	3	1	3
Constipation	4	9	9	10	14
Diarrhea	9	11	9	7	5
Dry mouth	9	11	17	21	25
Dyspepsia	4	2	3	3	5
Flatulence	1	2	2	2	2
Nausea	10	22	26	36	41
Stomach discomfort	1	2	1	1	1
Vomiting	3	3	4	6	9
<b>General disorders and administration site conditions</b>					
Chest Pain	0	0	1	1	2
Chills	1	1	<1	3	4
Fatigue	4	7	7	10	11
Feeling jittery	1	1	2	3	3
Irritability	1	2	2	2	2
<b>Infections and infestations</b>					
Gastroenteritis viral	1	0	1	2	<1
Influenza	1	1	1	2	4
Sinusitis	1	2	1	2	2
Urinary tract infection	<1	1	1	1	2
<b>Injury, poisoning and procedural complications</b>					
Accidental overdose	1	0	1	1	2
<b>Investigations</b>					
Blood pressure increased	1	1	1	2	2
Weight decreased	1	2	1	1	2
<b>Metabolism and nutrition disorders</b>					
Decreased appetite	2	5	8	10	10
Increased appetite	1	2	1	0	1
<b>Musculoskeletal and connective tissue disorders</b>					
Muscle spasms	1	2	3	2	2
Muscle tightness	1	1	2	1	<1
<b>Nervous system disorders</b>					
Disturbance in attention	<1	<1	1	2	1
Dizziness	5	13	10	15	16
Dysgeusia	1	1	1	1	2
Headache	23	20	22	29	25
Migraine	1	1	<1	1	2

**Table 2: Treatment Emergent Adverse Events ( $\geq 2\%$  in Any Desvenlafaxine extended-release tablet Group and More Frequent than Placebo): Percentage of Subjects in Short-Term, Placebo-Controlled MDD Studies**

System Organ Class Preferred Term	Percentage of Patients Reporting Reaction				
	Placebo (n=636)	Desvenlafaxine extended-release tablets			
		50 mg (n=317)	100 mg (n=424)	200 mg (n=307)	400 mg (n=317)
Paresthesia	1	2	2	1	3
Sedation	1	2	4	3	4
Somnolence	4	4	9	12	12
Tremor	2	2	3	9	9
<b>Psychiatric disorders</b>					
Abnormal dreams	1	2	3	2	4
Agitation	1	0	1	1	3
Anorgasmia	0	<1	2	2	6
Anxiety	2	3	5	4	4
Initial insomnia	1	2	2	0	2
Insomnia	6	9	12	14	15
Libido decreased	1	2	3	3	2
Middle insomnia	1	1	1	3	3
Nervousness	1	<1	1	2	2
Orgasm abnormal	<1	1	1	1	2
Sleep disorder	<1	1	<1	2	1
<b>Renal and urinary disorders</b>					
Dysuria	<1	<1	0	3	2
Urinary hesitation	0	<1	1	2	2
<b>Reproductive system and breast disorder</b>					
Dysmenorrhea	1	0	1	2	<1
Ejaculation delayed	<1	<1	2	3	3
Ejaculation disorder	0	0	1	1	2
Erectile dysfunction	1	1	2	3	5
<b>Respiratory, thoracic and mediastinal disorders</b>					
Yawning	<1	1	1	4	3
<b>Skin and subcutaneous tissue disorders</b>					
Hyperhidrosis	4	10	11	18	21
Night sweats	1	2	1	1	1
Rash	<1	1	1	2	<1
<b>Vascular disorders</b>					
Hot flush	<1	1	1	2	2
Hypertension	1	1	1	2	1

### Sexual Dysfunction Treatment Emergent Adverse Reactions

Table 3 shows the incidence of sexual dysfunction treatment emergent adverse events that occurred in  $\geq 1\%$  desvenlafaxine extended-release tablet-treated MDD patients in any fixed dose group (8-week, placebo-controlled, fixed and flexible-dose, pre-marketing clinical trials).

**Table 3: Sexual Dysfunction Treatment Emergent Adverse Events ( $\geq 1\%$  in Men or Women in any Desvenlafaxine extended-release tablet Group) During the On-Therapy Period: Percentage of Subjects in Short-Term, Placebo-Controlled MDD Studies**

	Desvenlafaxine extended-release tablets			
--	---	--	--	--

**Table 3: Sexual Dysfunction Treatment Emergent Adverse Events ( $\geq 1\%$  in Men or Women in any Desvenlafaxine extended-release tablet Group) During the On-Therapy Period: Percentage of Subjects in Short-Term, Placebo-Controlled MDD Studies**

	Placebo (n=239)	50 mg (n=108)	100 mg (n=157)	200 mg (n=131)	400 mg (n=154)
<b>Men only</b>					
Anorgasmia	0	0	3	5	8
Libido decreased	1	4	5	6	3
Orgasm abnormal	0	0	1	2	3
Ejaculation delayed	<1	1	5	7	6
Erectile dysfunction	1	3	6	8	11
Ejaculation disorder	0	0	1	2	5
Ejaculation failure	0	1	0	2	2
Sexual dysfunction	0	1	0	0	2
<b>Desvenlafaxine extended-release tablets</b>					
	Placebo (n=397)	50 mg (n=209)	100 mg (n=267)	200 mg (n=176)	400 mg (n=163)
<b>Women only</b>					
Anorgasmia	0	1	1	0	3

### Other Treatment Emergent Adverse Events Observed During Pre-Market and Post-Market Clinical Trials

#### All MDD Clinical Trials

The following is a list of MedDRA preferred terms that reflect treatment-emergent adverse events that were reported by patients treated with desvenlafaxine extended-release tablets throughout the dose ranges studied (10 to 400 mg) during both short-term and long-term clinical trials. In general, the adverse events were most frequent in the first week of treatment.

Treatment Emergent Adverse Events are categorized by system organ class and listed in order of decreasing frequency using the following definitions:

Very common:  $\geq 10\%$  of patients

Common:  $\geq 1\%$  and  $< 10\%$  of patients

Uncommon:  $\geq 0.1\%$  and  $< 1\%$  of patients

Rare:  $\geq 0.01\%$  and  $< 0.1\%$  of patients

Very rare:  $< 0.01\%$  of patients

System Organ Class	Treatment Emergent Adverse Events
<b>Immune System Disorders</b>	
Uncommon	Hypersensitivity

<b>System Organ Class</b>	<b>Treatment Emergent Adverse Events</b>
<b>Metabolism and Nutrition Disorders</b>	
Common	Decreased appetite
Rare	Hyponatraemia
<b>Psychiatric Disorders</b>	
Very common	Insomnia
Common	Withdrawal syndrome, anxiety, nervousness, abnormal dreams, irritability, libido decreased, anorgasmia
Uncommon	Depersonalisation, orgasm abnormal
Rare	Mania, hypomania, hallucination
<b>Nervous System Disorders</b>	
Very common	Headache, dizziness, somnolence
Common	Tremor, paraesthesia, disturbance in attention, dysgeusia
Uncommon	Syncope, dyskinesia
Rare	Convulsion, dystonia
<b>Eye Disorders</b>	
Common	Vision blurred, mydriasis
<b>Ear and Labyrinth Disorders</b>	
Common	Vertigo, tinnitus
<b>Cardiac Disorders</b>	
Common	Palpitations, tachycardia
<b>Vascular Disorders</b>	
Common	Blood pressure increased, hot flush
Uncommon	Orthostatic hypotension, peripheral coldness
<b>Respiratory, Thoracic and Mediastinal Disorders</b>	
Common	Yawning
Uncommon	Epistaxis
<b>Gastrointestinal Disorders</b>	
Very common	Nausea, dry mouth
Common	Constipation, diarrhea, vomiting
<b>Skin and Subcutaneous Tissue Disorders</b>	
Very common	Hyperhidrosis
Common	Rash
Uncommon	Alopecia
Rare	Angioedema, photosensitivity reaction
<b>Musculoskeletal and Connective Tissue and Bone Disorders</b>	
Common	Musculoskeletal stiffness
<b>Renal and Urinary Disorders</b>	
Uncommon	Urinary retention, urinary hesitation, proteinuria
<b>Reproductive System and Breast Disorders</b>	
Common	Erectile dysfunction, ejaculation delayed
Uncommon	Ejaculation disorder, ejaculation failure, sexual dysfunction
<b>General Disorders and Administration Site Conditions</b>	
Common	Fatigue, asthenia, chills, feeling jittery
<b>Investigations</b>	
Common	Liver function test abnormal, weight increased, weight decreased
Uncommon	Blood cholesterol increased, blood triglycerides increased, blood prolactin increased

ADR = adverse drug reaction; MDD = major depressive disorder.

### **Ischemic cardiac adverse events**

In clinical trials, there were uncommon reports of ischemic cardiac adverse events, including myocardial ischemia, myocardial infarction, and coronary occlusion requiring revascularization; these patients had multiple underlying cardiac risk factors. More patients experienced these events



during desvenlafaxine treatment as compared to placebo (see [WARNINGS AND PRECAUTIONS/Cardiovascular/Cerebrovascular](#)).

### Discontinuation Symptoms

Adverse drug reactions reported in association with abrupt discontinuation, dose reduction or tapering of treatment in MDD pre-market clinical trials at a rate of  $\geq 5\%$  include: dizziness, nausea, headache, irritability, diarrhea, anxiety, abnormal dreams, fatigue, and hyperhidrosis. In general, discontinuation events occurred more frequently with longer duration of therapy (see [DOSAGE AND ADMINISTRATION](#) and [WARNINGS AND PRECAUTIONS](#)).

### Orthostatic Hypotension

Of the 4,158 patients in pre-market clinical trials with desvenlafaxine extended-release tablets, 6% were 65 years of age or older. No overall differences in safety or efficacy were detected between these subjects and younger subjects. However, there was a higher incidence of orthostatic hypotension in patients  $\geq 65$  years of age compared to patients  $< 65$  years of age treated with desvenlafaxine. Greater sensitivity of some older individuals cannot be ruled out. For elderly patients, possible reduced renal clearance of desvenlafaxine should be considered when determining dose (see [DOSAGE AND ADMINISTRATION](#), [Dosing Considerations](#), [Geriatrics](#) and [ACTION AND CLINICAL PHARMACOLOGY, Geriatrics](#)).

### ECG Changes

Electrocardiograms were obtained from 1,492 desvenlafaxine extended-release tablet-treated patients with major depressive disorder and 984 placebo-treated patients in pre-market clinical trials lasting up to 8 weeks. No clinically relevant differences were observed between desvenlafaxine extended-release tablet-treated and placebo-treated patients for QT, QTc, PR, and QRS intervals. In a thorough QTc study with prospectively determined criteria, desvenlafaxine did not cause QT prolongation. No difference was observed between placebo and desvenlafaxine treatments for the QRS interval (see [ACTION AND CLINICAL PHARMACOLOGY](#)).

A thorough QTc study was designed to assess the potential effect of 200 and 600 mg of desvenlafaxine extended-release tablets on QT interval prolongation.

**Table 4: Estimated and 90% Confidence Interval for QT<sub>c</sub> changes from Time-Matched Baseline Relative to Placebo at Hour 8 after Dose with Different Heart Rate Corrections<sup>a</sup>**

Treatment	Fridericia's QT Correction (ms)	Population QT Correction (ms)
<b>Desvenlafaxine extended-release tablets 200 mg<sup>b</sup></b>	1.5 (-0.88, 3.88)	3.18 (0.87, 5.50)
<b>Desvenlafaxine extended-release tablets 600 mg<sup>b</sup></b>	-2.43 (-4.90, 0.04)	0.98 (-1.42, 3.38)
Moxifloxacin 400 mg (Active control)	10.80 (8.44, 13.16)	10.92 (8.62, 13.22)

a. Mean (90% confidence intervals)

b. The **Desvenlafaxine extended-release tablet** doses of 200 and 600 mg were 2 and 6 times the maximum

recommended dose, respectively.

## Abnormal Hematologic and Clinical Chemistry Findings

### Serum Lipids

Elevations in fasting serum total cholesterol, LDL cholesterol, and triglycerides occurred in the controlled trials. Some of these abnormalities were considered potentially clinically significant (see **WARNINGS AND PRECAUTIONS, Serum Cholesterol Elevation** and **Monitoring and Laboratory Tests, Serum Lipids**).

The percentage of subjects who exceeded a predetermined threshold for values of outliers is represented in Table 5.

**Table 5: Proportion (%) of Subjects With Lipid Abnormalities of Potential Clinical Significance for All Short-Term, Placebo-Controlled Clinical Trials**

	-----Desvenlafaxine extended-release tablets-----					
	Placebo <sup>a</sup>	50 mg	100 mg	200 mg	400 mg	50-400 mg <sup>a</sup>
<b>Total Cholesterol</b>						
Increase $\geq 1.29$ mmol/L and absolute value $\geq 6.75$ mmol/L	2	3	4	4	10	5
<b>LDL Cholesterol</b>						
Increase $\geq 1.29$ mmol/L and absolute value $\geq 4.91$ mmol/L	<1	1	0	1	2	1
<b>Triglycerides</b>						
$\geq 3.7$ mmol/L	3	2	1	4	6	3

a. Includes data from all short-term, placebo-controlled studies including fixed-dose and flexible-dose studies.

### Proteinuria

In pre-market placebo-controlled studies 6.4% of subjects treated with desvenlafaxine extended-release tablets had treatment-emergent proteinuria. Proteinuria was usually of trace amounts and was not associated with increases in BUN or creatinine or adverse events. The mechanism of the enhanced protein excretion is not clear but may be related to noradrenergic stimulation.

### Vital Sign Changes

Tables 6 and 7 summarize the changes that were observed in pre-market placebo-controlled, short-term, premarketing trials with desvenlafaxine extended-release tablets in patients with MDD.

**Table 6: Mean Changes, Vital Signs, at Final On-Therapy for All Short term, Fixed-dose Controlled Trials**

---Desvenlafaxine extended-release tablets---

	Placebo	50 mg	100 mg	200 mg	400 mg
<b>Blood Pressure</b>	-1.4	1.2	2.0	2.5	2.1
Supine systolic bp (mm Hg)					
Supine diastolic bp (mm Hg)	-0.6	0.7	0.8	1.8	2.3
<b>Pulse rate</b>					
Supine pulse (bpm)	-0.3	1.3	1.3	0.9	4.1
<b>Weight (kg)</b>	0.0	-0.4	-0.6	-0.9	-1.1

At the final on-therapy assessment in the 6-month, double-blind, placebo-controlled phase of a long-term trial in patients who had responded to desvenlafaxine extended-release tablets during the initial 12-week, open-label phase, there was no statistical difference in mean weight change between desvenlafaxine extended-release tablets- and placebo-treated patients.

Table 7 provides the incidence of patients meeting criteria for sustained hypertension (defined as treatment-emergent supine diastolic blood pressure  $\geq 90$  mm Hg and  $\geq 10$  mm Hg above baseline for 3 consecutive visits).

**Table 7: Incidence (%) of Patients with Sustained Hypertension for All Short-Term Fixed-Dose Clinical Trials**

	Placebo	---Desvenlafaxine extended-release tablets---			
		50 mg	100 mg	200 mg	400 mg
<b>Sustained hypertension</b>	0.5	1.3	0.7	1.1	2.3

### Adverse Drug Reactions in Pediatrics (<18 years of age)

The safety and efficacy of **Taro-Desvenlafaxine** in children under the age of 18 years have not been established, and it is not indicated for this population. (see **WARNINGS AND PRECAUTIONS**, Special Populations, Pediatrics).

All of the adverse events described above for adults with MDD should be considered in the case of children and adolescents taking **Taro-Desvenlafaxine**. Additional adverse events of note (including laboratory values and vitals) are summarized below.

The listed events are those identified as worse in children compared to adults at the recommended therapeutic dose, due to greater frequency rates and/or greater differential from placebo.

**Table 8: Adverse Events during short-term (8 weeks) treatment of children and adolescents with Major Depressive Disorder that were identified as worse in pediatrics compared to adults, or unique to pediatrics and greater than placebo**

Age Group	Desvenlafaxine extended-release tablets		Placebo	
	Frequency	n/N	Frequency	n/N
<b>Pooled (Ages 7-11 and 12-17)</b>				
Weight loss <sup>1</sup> (≥3.5% of baseline weight)	17%	60/356*	7%	16/231*
Upper abdominal pain <sup>2</sup>	10%	34/358	7%	16/232
<b>Age 7-11</b>				
Diarrhea <sup>2</sup>	7%	8/116	1%	1/78
Triglycerides <sup>1</sup> (increase > 2.258 mmol/L)	19%	19/102*	7%	5/72*
Hemoglobin in urine <sup>1</sup>	6%	6/102*	3%	2/72*
Orthostatic Systolic Blood Pressure <sup>1</sup> (decrease ≥ 20 mg Hg from supine to standing)	8%	9/116	1%	1/78
<b>Ages 12-17</b>				
Back/Flank pain <sup>2</sup>	3%	8/242	0%	0/154

\*Number of subjects with non-missing test result

<sup>1</sup>Laboratory test or clinical measurement result

<sup>2</sup>Reported MedDRA term

The risks associated with longer term desvenlafaxine extended-release tablet use were assessed in 6-month, open-label extension studies in pediatric patients (7 to 17 years of age) with MDD. In the total desvenlafaxine extended-release tablet-exposed population, the frequency of weight loss ≥ 3.5% was 23% (156/684), with persistence of weight loss at study end in approximately 22% of these cases (35/156).

The long-term safety, including effects on growth, maturation and behavioural development in patients under 18 years of age has not been systematically evaluated.

### Suicidality-Related Events:

In the desvenlafaxine pediatric studies, the totality of suicidality-related behaviours and ideation are captured by the Columbia Suicide Severity Rating Scale (C-SSRS), performed at all scheduled visits. The incidence rates below exclude events classified as “self-injurious behavior, no suicidal intent”.

In the two pooled, placebo-controlled 8 week studies, the incidence of suicidality-related events is 12.1% (28/231) for placebo and 12.6% (45/356) for desvenlafaxine extended-release tablets. In the 26-week, open-label extension studies that included the above trials, the incidence of suicidality-related events is 15.4% (105/680).

The safety and efficacy of **Taro-Desvenlafaxine** in children under the age of 18 years have not been established and its uses is not recommended.

### **Adverse Events Identified During Post-Approval Use**

The following adverse events have been identified during post-approval use of desvenlafaxine extended-release tablets. Because post-approval reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency:

**Cardiac Disorders:** stress cardiomyopathy (Takotsubo cardiomyopathy)

**Gastrointestinal** – gastrointestinal bleeding, pancreatitis acute

**Nervous System Disorders:** serotonin syndrome

**Skin and subcutaneous tissue disorders** – Stevens-Johnson Syndrome, toxic epidermal necrolysis, erythema multiforme

## **DRUG INTERACTIONS**

### **Serious Drug Interactions**

Monoamine Oxidase Inhibitors: See **CONTRAINDICATIONS**, and **Drug-Drug interactions** below.

### **Overview**

Selected drug interaction studies were performed. The combination of linear pharmacokinetics, a simple metabolic profile without the potential for CYP polymorphism factors, weak interactions with selected probe substrates, and low protein binding results in a low potential for the interaction of desvenlafaxine with other prescribed medications.

### **Drug-Drug Interactions**

#### **Monoamine Oxidase Inhibitors**

Desvenlafaxine succinate is contraindicated in patients taking MAOIs. Desvenlafaxine succinate must not be used in combination with a monoamine oxidase inhibitor (MAOI), or within at least 14 days of discontinuing treatment with an MAOI. Based on the half-life of desvenlafaxine succinate, at least 7 days should be allowed after stopping desvenlafaxine succinate before starting an MAOI (see **CONTRAINDICATIONS**).

#### **Serotonin Syndrome**

As with other serotonergic agents, serotonin syndrome, a potentially life-threatening condition, may occur with desvenlafaxine treatment, particularly with concomitant use of other agents that may affect the serotonergic neurotransmitter system (including triptans, SSRIs, other SNRIs, amphetamines, lithium, sibutramine, fentanyl and its analogues, dextromethorphan, tramadol, tapentadol, meperidine, methadone and pentazocine or St. John's Wort [*Hypericum perforatum*], with drugs which impair metabolism of serotonin (such as MAOIs, including linezolid [an antibiotic which is a reversible non-selective MAOI], and methylene blue; see

**CONTRAINDICATIONS**), or with serotonin precursors (such as tryptophan supplements). Serotonin syndrome symptoms may include mental status changes, autonomic instability, neuromuscular aberrations and/or gastrointestinal symptoms (see **WARNINGS AND PRECAUTIONS**).

If concomitant treatment of desvenlafaxine with an SSRI, an SNRI or a 5-hydroxytryptamine receptor agonist (triptan) is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases. The concomitant use of desvenlafaxine with serotonin precursors (such as tryptophan supplements) is not recommended.

### **Central Nervous System (CNS) Active Agents**

The risk of using desvenlafaxine succinate in combination with other CNS-active drugs has not been systematically evaluated. Consequently, caution is advised when desvenlafaxine succinate is taken in combination with other CNS-active drugs.

### **Drugs Affecting Platelet Function (e.g., NSAIDs, ASA, and other anticoagulants)**

Serotonin release by platelets plays an important role in hemostasis. Epidemiological studies of the case-control and cohort design that have demonstrated an association between use of psychotropic drugs that interfere with serotonin reuptake and the occurrence of upper gastrointestinal bleeding have also shown that concurrent use of an NSAID, ASA or other anticoagulants may potentiate this risk of bleeding.

Altered anticoagulant effects, including increased bleeding, have been reported when SSRIs or SNRIs are co-administered with warfarin. Patients receiving warfarin therapy should be carefully monitored when **Taro-Desvenlafaxine** is initiated or discontinued (see **WARNINGS AND PRECAUTIONS, Hematologic, Abnormal Bleeding**).

### **Potential for other drugs to affect desvenlafaxine succinate (see also **ACTION AND CLINICAL PHARMACOLOGY**)**

#### *Inhibitors of CYP3A4*

CYP3A4 is a minor pathway for the metabolism of **Taro-Desvenlafaxine**. In a clinical study, ketoconazole (200 mg BID) increased the area under the concentration vs. time curve AUC of desvenlafaxine extended-release tablets (400 mg single dose) by about 43% and C<sub>max</sub> by about 8%. Concomitant use of **Taro-Desvenlafaxine** with potent inhibitors of CYP3A4 may result in higher concentrations of **Taro-Desvenlafaxine**.

#### *Inhibitors of other CYP enzymes*

Based on in vitro data, drugs that inhibit CYP isozymes 1A1, 1A2, 2A6, 2D6, 2C8, 2C9, 2C19, and 2E1 are not expected to have significant impact on the pharmacokinetic profile of desvenlafaxine.

### **Potential for desvenlafaxine to affect other drugs (see also **ACTION AND CLINICAL PHARMACOLOGY**)**

### *Drugs metabolized by CYP2D6*

Clinical studies have shown that desvenlafaxine does not have a clinically relevant effect on CYP2D6 metabolism at the dose of 100 mg daily. When desvenlafaxine succinate was administered at a dose of 100 mg daily in conjunction with a single 50 mg dose of desipramine, a CYP2D6 substrate, the AUC of desipramine increased approximately 17%. When 400 mg of desvenlafaxine was administered (8 times the recommended 50 mg dose), the AUC of desipramine increased approximately 90%. When desvenlafaxine succinate was administered at a dose of 100 mg daily in conjunction with a single 60 mg dose of codeine, a CYP2D6 substrate metabolized to morphine, the AUC of codeine was unchanged, the AUC of morphine decreased approximately 8%. Concomitant use of desvenlafaxine with a drug metabolized by CYP2D6 may result in increased concentrations of that drug and decreased concentrations of its CYP2D6 metabolites.

### *Drugs metabolized by CYP3A4*

In vitro, desvenlafaxine does not inhibit or induce the CYP3A4 isozyme. In a clinical study, desvenlafaxine (400 mg daily) was co-administered with a single 4 mg dose of midazolam (a CYP3A4 substrate). The AUC and  $C_{max}$  of midazolam decreased by approximately 31% and 16%, respectively. In a second study, desvenlafaxine 50 mg daily was co-administered with a single 4 mg dose of midazolam. The AUC and  $C_{max}$  of midazolam decreased by approximately 29% and 14%, respectively. Concomitant use of desvenlafaxine with a drug metabolized by CYP3A4 may result in lower exposure to that drug.

### *Drugs metabolized by a combination of both CYP2D6 and CYP3A4*

Clinical studies with aripiprazole and tamoxifen suggest that desvenlafaxine at twice the recommended dose (100 mg daily) does not have a clinically relevant effect on drugs metabolized by a combination of both CYP2D6 and CYP3A4 enzymes.

Desvenlafaxine succinate was studied at a dose of 100 mg daily in conjunction with a single 5 mg dose of aripiprazole, a CYP2D6 and CYP3A4 substrate metabolized to the active metabolite dehydroaripiprazole.

A single 40 mg dose of tamoxifen, which is metabolized to active metabolites 4-hydroxy- tamoxifen and endoxifen by CYP2D6 and CYP3A4, was also studied in conjunction with desvenlafaxine succinate (100 mg daily).

### *Drugs metabolized by CYP1A2, 2A6, 2C8, 2C9 and 2C19*

In vitro, desvenlafaxine does not inhibit CYP1A2, 2A6, 2C8, 2C9, and 2C19 isozymes and would not be expected to affect the pharmacokinetics of drugs that are metabolized by these CYP isozymes.

## **Electroconvulsive Therapy**

There are no clinical data establishing the risks and/or benefits of electroconvulsive therapy combined with desvenlafaxine extended-release tablet treatment for MDD.

## **P-glycoprotein transporter**

In vitro, desvenlafaxine is not a substrate or an inhibitor for the P-glycoprotein transporter. The pharmacokinetics of desvenlafaxine are unlikely to be affected by drugs that inhibit the P-glycoprotein transporter and desvenlafaxine is not likely to affect the pharmacokinetics of drugs that are substrates of the P-glycoprotein transporter.

### **Drug-Food Interactions**

Food does not alter the bioavailability of desvenlafaxine.

### **Drug-Herb Interactions**

#### *St. John's Wort*

In common with SSRI's, pharmacodynamic interactions between **Taro-Desvenlafaxine** and the herbal remedy St. John's Wort may occur and may result in an increase in undesirable effects (see **DRUG INTERACTIONS, Serotonin Syndrome**).

### **Drug-Laboratory Interactions**

False positive urine immunoassay screening tests for phencyclidine (PCP) and amphetamine have been reported in patients taking desvenlafaxine extended-release tablets. This is due to lack of specificity of the screening tests. False positive test results may be expected for several days following discontinuation of **Taro-Desvenlafaxine** therapy. Confirmatory tests, such as gas chromatography/mass spectrometry, will distinguish **Taro-Desvenlafaxine** from PCP and amphetamine.

### **Drug-Lifestyle Interactions**

#### *Ethanol*

As with all CNS-active drugs, patients should be advised to avoid alcohol consumption while taking desvenlafaxine succinate.

### **Interference with Cognitive and Motor Performance**

A clinical study that assessed the effects of desvenlafaxine on behavioral performance of healthy individuals did not reveal clinically significant impairment of psychomotor, cognitive, or complex behavior performance. However, since any CNS-active drug may impair judgment, thinking, or motor skills, patients should be cautioned about operating hazardous machinery, including automobiles, until they are reasonably certain that **Taro-Desvenlafaxine** therapy does not adversely affect their ability to engage in such activities.

## **DOSAGE AND ADMINISTRATION**

### **General**

**Taro-Desvenlafaxine is not indicated for use in children under 18 years of age (see **WARNINGS AND PRECAUTIONS, Potential Association with Behavioural and Emotional Changes, Including Self-Harm**).**



## Recommended Dose and Dosage Adjustment

### *Initial Treatment*

The recommended starting dose of **Taro-Desvenlafaxine** (desvenlafaxine extended-release tablets) is 50 mg once daily, with or without food. In clinical studies, no additional benefit was demonstrated at doses greater than 50 mg/day. If the physician, based on clinical judgment, decides a dose increase above 50 mg/day is warranted for an individual patient, the maximum recommended dose should not exceed 100 mg/day. In clinical studies, doses of 50-400 mg/day were shown to be effective, although no additional benefit was demonstrated at doses greater than 50 mg/day, and adverse events and discontinuations were more frequent at higher doses. Patients should be periodically reassessed to determine the need for continued treatment.

### *Maintenance/Continuation/Extended Treatment*

It is generally agreed that acute episodes of major depression require several months or longer of sustained pharmacologic therapy beyond response to the acute episode. Long-term efficacy of desvenlafaxine extended-release tablets (50 daily) for up to 26 weeks, following response during 20 weeks of acute, open-label treatment, was established in a placebo-controlled trial. Patients should be periodically reassessed to determine the need for maintenance treatment.

It is recommended that **Taro-Desvenlafaxine** be taken at approximately the same time each day. **Taro-Desvenlafaxine** tablets must be swallowed whole with liquids, and must not be chewed, divided or crushed. Due to the controlled-release design, **Taro-Desvenlafaxine** tablets should only be used in patients who are able to swallow the tablets whole.

### **Missed Dose**

A patient missing a dose should take it as soon as they remember to. If it is almost time for the next dose, the missed dose should be skipped. The patient should be cautioned against taking two doses concomitantly to “make up” for the missed dose.

### **Discontinuing Taro-Desvenlafaxine**

Symptoms associated with discontinuation of **Taro-Desvenlafaxine**, other SNRIs and SSRIs have been reported (see **WARNINGS AND PRECAUTIONS, Discontinuation Symptoms and ADVERSE REACTIONS, Discontinuation symptoms**). Patients should be monitored for these symptoms when discontinuing treatment. A gradual reduction in the dose rather than abrupt cessation is recommended. If intolerable symptoms occur following a decrease in the dose or upon discontinuation of treatment, then resuming the previously prescribed dose may be considered. Subsequently, the physician may continue decreasing the dose, but at a more gradual rate. In some patients, discontinuation may need to occur over periods of months or longer.

### **Switching Patients from Other Antidepressants to Taro-Desvenlafaxine**

Discontinuation symptoms have been reported when switching patients from other antidepressants, including venlafaxine, to **Taro-Desvenlafaxine**. Tapering of the initial antidepressant may be necessary to minimize discontinuation symptoms (see **CONTRAINDICATIONS**).

### **Switching Patients to or from a Monoamine Oxidase Inhibitor**

At least 14 days should elapse between discontinuation of an MAOI and initiation of therapy with **Taro-Desvenlafaxine**. In addition, based on the half-life of desvenlafaxine succinate, at least 7 days should be allowed after stopping desvenlafaxine succinate before starting an MAOI.

#### **Use of Taro-Desvenlafaxine with Reversible MAOIs such as Linezolid or Methylene Blue**

Do not start **Taro-Desvenlafaxine** in a patient who is being treated with a reversible MAOI such as linezolid or in whom intravenous methylene blue has been administered because there is increased risk of serotonin syndrome (see **CONTRAINDICATIONS**). In a patient who requires more urgent treatment of a psychiatric condition, non-pharmacological interventions, including hospitalization, should be considered.

In some cases, a patient already receiving **Taro-Desvenlafaxine** therapy may require urgent treatment with linezolid or intravenous methylene blue. If acceptable alternatives to linezolid or intravenous methylene blue treatment are not available and the potential benefits of linezolid or intravenous methylene blue are judged to outweigh the risks of serotonin syndrome in a particular patient, **Taro-Desvenlafaxine** should be stopped promptly, and linezolid or intravenous methylene blue can be administered. The patient should be monitored for symptoms of serotonin syndrome for two weeks or until 24 hours after the last dose of linezolid or intravenous methylene blue, whichever comes first (see **WARNINGS AND PRECAUTIONS**). Therapy with **Taro-Desvenlafaxine** may be resumed 24 hours after the last dose of linezolid or intravenous methylene blue.

#### **Dosing Considerations**

##### **Patients with severe renal impairment and end-stage renal disease**

The recommended dose in patients with severe renal impairment (24-hr CrCl < 30 mL/min) or end-stage renal disease (ESRD) is 50 mg every other day. Because of individual variability in clearance in these patients, individualization of dosage may be desirable. Supplemental doses should not be given to patients after dialysis (see **ACTION AND CLINICAL PHARMACOLOGY, Renal Insufficiency**).

##### **Use in patients with hepatic impairment**

No dosage adjustment is necessary for patients with hepatic impairment (see **ACTION AND CLINICAL PHARMACOLOGY, Hepatic Insufficiency**).

##### **Geriatrics (≥ 65 years of age)**

No dosage adjustment is required solely on the basis of age; however, possible reduced clearance of **Taro-Desvenlafaxine** should be considered when determining dose (see **ACTION AND CLINICAL PHARMACOLOGY, Geriatrics**).

##### **Pediatrics**

**Taro-Desvenlafaxine** is not indicated for use in children under the age of 18. Two placebo controlled studies in 587 pediatric patients 7 to 17 years of age with MDD failed to demonstrate

efficacy; neither short-term, placebo-controlled study demonstrated statistically or clinically significant differences between desvenlafaxine extended-release tablets and placebo (see **WARNINGS AND PRECAUTIONS**, Potential Association with Behavioural and Emotional Changes, Including Self-Harm; **ACTION AND CLINICAL PHARMACOLOGY**, Pediatrics).

### **Discontinuation of Therapy**

A gradual reduction in the dose rather than abrupt cessation is recommended whenever possible. Discontinuation regimens should take into account the individual circumstances of the patient, such as duration of treatment and dose at discontinuation (see **WARNINGS AND PRECAUTIONS** and **ADVERSE REACTIONS**).

## **OVERDOSAGE**

### **Human Experience**

There is limited clinical experience with desvenlafaxine succinate overdose in humans. In pre-marketing clinical trials, no cases of fatal acute overdose of desvenlafaxine succinate were reported.

Among the patients included in the pre-marketing major depressive disorder trials of desvenlafaxine succinate, there were four adults who ingested doses over 800 mg of desvenlafaxine (4000 mg [desvenlafaxine alone], 900, 1800 and 5200 mg [in combination with other drugs]); all patients recovered. In addition, a patient's 11 month-old child accidentally ingested 600 mg of desvenlafaxine, was treated and recovered.

The adverse reactions reported within 5 days of an overdose > 600 mg that were possibly related to desvenlafaxine included: headache, vomiting, agitation, dizziness, nausea, constipation, diarrhea, dry mouth, paresthesia, and tachycardia.

Desvenlafaxine is the major active metabolite of venlafaxine. Overdose experience reported with venlafaxine (the parent drug of desvenlafaxine) is presented below; the identical information can be found in the *Overdosage* section of the venlafaxine Product Monograph.

### *Post marketing Experience with EFFEXOR*

In post marketing experience, overdose with venlafaxine was reported predominantly in combination with alcohol and/or other drugs. The most commonly reported events in overdose include tachycardia, changes in level of consciousness (ranging from somnolence to coma), mydriasis, convulsion, and vomiting. Electrocardiographic changes (e.g., prolongation of QT interval, bundle branch block, QRS prolongation), ventricular tachycardia, bradycardia, hypotension, delayed rise in plasma creatine kinase levels, rhabdomyolysis, liver necrosis, serotonin syndrome, vertigo, and death have been reported. Muscle enzymes should be monitored in patients with venlafaxine overdose to detect development of rhabdomyolysis at an early stage and to initiate appropriate treatment. According to post-marketing overdose reports with venlafaxine (where overdose amounts were provided) fatal acute overdoses have been reported with venlafaxine alone at doses as low as approximately 1 gram.

Published retrospective studies report that venlafaxine overdosage may be associated with an increased risk of fatal outcomes compared to that observed with SSRI antidepressant products, but

lower than that for tricyclic antidepressants. Epidemiological studies have shown that venlafaxine-treated patients have a higher burden of suicide risk factors than SSRI patients. The extent to which the finding of an increased risk of fatal outcomes can be attributed to the toxicity of venlafaxine in overdose as opposed to some characteristics of venlafaxine-treated patients is not clear.

Prescriptions for **Taro-Desvenlafaxine** should be written for the smallest quantity of drug consistent with good patient management, in order to reduce the risk of overdose.

### **Management of Overdosage**

Treatment should consist of those general measures employed in the management of overdose with any SSRI/SNRI.

Induction of emesis is not recommended. Because of the moderate volume of distribution of this drug, forced diuresis, dialysis, hemoperfusion, and exchange transfusion are unlikely to be of benefit. No specific antidotes for desvenlafaxine are known.

Ensure an adequate airway, oxygenation, and ventilation. Monitor cardiac rhythm and vital signs. General supportive and symptomatic measures are also recommended. Gastric lavage with a large-bore orogastric tube with appropriate airway protection, if needed, may be indicated if performed soon after ingestion or in symptomatic patients. Activated charcoal should be administered.

In managing an overdose, consider the possibility of multiple drug involvement. The physician should consider contacting a poison control center for additional information on the treatment of any overdose.

For the management of suspected drug overdose, contact your regional Poison Control Centre.
---

## **ACTION AND CLINICAL PHARMACOLOGY**

### **Mechanism of Action**

Desvenlafaxine is the major active metabolite of venlafaxine which is also approved for treatment of depression. Preclinical studies have shown that desvenlafaxine succinate is a selective serotonin and norepinephrine reuptake inhibitor. The clinical efficacy of desvenlafaxine succinate is thought to be related to the potentiation of these neurotransmitters in the central nervous system.

### **Pharmacodynamics**

Desvenlafaxine lacked significant affinity for numerous receptors, including muscarinic-cholinergic, H<sub>1</sub>-histaminergic, or  $\alpha_1$ -adrenergic receptors in vitro. Desvenlafaxine also lacked significant affinity for various ion channels, including calcium, chloride, potassium and sodium ion channels and also lacked monoamine oxidase (MAO) inhibitory activity. Desvenlafaxine lacked significant activity in the in vitro cardiac potassium channel (hERG) assay.

### **Pharmacokinetics**

The single dose pharmacokinetics of desvenlafaxine are linear and dose-proportional in a dose range of 50 to 600 mg/day. The mean terminal half-life,  $t_{1/2}$ , is approximately 11 hours. With once-daily dosing, steady-state plasma concentrations are achieved within approximately 4 - 5 days. At steady state, multiple-dose accumulation of desvenlafaxine is linear and predictable from the single-dose pharmacokinetic profile.

The pharmacokinetics of desvenlafaxine have been thoroughly evaluated in women and men. There are minimal differences based on gender; data from all subjects are presented below.

### **Absorption and Distribution:**

The absolute oral bioavailability of desvenlafaxine extended-release tablets after oral administration is about 80%. Mean time to peak plasma concentrations ( $t_{max}$ ) is about 7.5 hours after oral administration.

A food-effect study involving administration of desvenlafaxine extended-release tablets to healthy volunteers under fasting and fed conditions (high-fat meal) indicated that the  $C_{max}$  was increased about 16% in the fed state, while the AUCs were similar. This difference is not clinically significant; therefore, **Taro-Desvenlafaxine** can be taken without regard to meals.

The plasma protein binding of desvenlafaxine is low (30%) and is independent of drug concentration. Desvenlafaxine's volume of distribution at steady-state following intravenous administration is 3.4 L/kg, indicating distribution into nonvascular compartments.

### **Metabolism and Excretion:**

Desvenlafaxine is primarily metabolized by conjugation (mediated by UGT isoforms) and, to a minor extent, through oxidative metabolism. CYP3A4 is the cytochrome P450 isozyme mediating the oxidative metabolism (N-demethylation) of desvenlafaxine. Approximately 45% of desvenlafaxine is excreted unchanged in urine at 72 hours after oral administration. Approximately 19% of the administered dose is excreted as the glucuronide metabolite and <5% as the oxidative metabolite (N,O-didesmethylvenlafaxine) in urine.

### **Special Populations and Conditions**

#### **Gender:**

In a trial of healthy subjects administered doses up to of 300 mg, women had an approximately 25% higher  $C_{max}$  and an approximately 10% higher AUC than age-matched men. No adjustment of dosage on the basis of gender is needed.

#### **Pediatrics:**

**Taro-Desvenlafaxine** is not indicated for use in children and adolescents. Two placebo controlled phase 3 studies in 587 pediatric patients 7 to 17 years of age with MDD failed to demonstrate efficacy; neither short term, placebo-controlled study demonstrated statistically or clinically significant differences between desvenlafaxine extended-release tablets and placebo (see also ADVERSE REACTIONS, Adverse Drug Reactions in Pediatrics (< 18 years of age)).

### Phase 2 Pharmacokinetic Study

In a phase 2, 8-week open-label pharmacokinetic, safety, and tolerability study in 59 pediatric patients with MDD, desvenlafaxine extended-release tablets 10, 25, 50, and 100 mg was administered to 29 children (7 to 11 years old) and desvenlafaxine extended-release tablets 25, 50, 100, and 200 mg was administered to 30 adolescents (12 to 17 years old). Mean CL/F (apparent oral dose clearance) values were higher in children (range: 0.441 to 0.540 L/h/kg) than values obtained in 397 adults (mean  $\pm$  SD: [0.31 $\pm$ 0.15 L/h/kg]). Mean CL/F values for adolescents (range: 0.282 to 0.441 L/hr./kg) were more comparable to CL/F values in adults. The effect of body weight on dose normalized AUC could be described by an exponential equation for each age group. Comparison of the predictions for AUC (normalized by dose) based on age and body weight or based only on body weight showed that body weight alone provides an adequate prediction for AUC. Mean urinary recovery of total desvenlafaxine and total N,O-didesmethylvenlafaxine ranged from 40% to 61% in children and 55 to 69% in adolescents. The pharmacokinetic results in pediatric patients from this study and the comparison with adults should be considered preliminary.

Twenty children and 20 adolescents who completed the pharmacokinetics study entered a 6-month, open-label, phase 2 extension safety study. The total daily dose of desvenlafaxine extended-release tablets was flexible between 10, 25, 50, and 100 mg for children, and between 25, 50, 100, and 200 mg for adolescents. Eighteen subjects (45%) completed the extension study.

In both studies combined, 28 subjects (70%) reported 1 or more treatment-emergent adverse event (TEAE). Four (20.0%) children and 3 (15.0%) adolescents reported adverse events that led to discontinuation of treatment: aggression (by 2 children), disturbance in attention and psychomotor hyperactivity (by 1 child), negativism (by 1 child) and nausea (by 1 adolescent), nausea and headache (by 1 adolescent), and pregnancy (by 1 adolescent). For children, the most common TEAEs during the on-therapy period of both studies combined were headache and abdominal pain reported by 3 (15.0%) and 3 (15.0%) of patients, respectively. For adolescents, the most common TEAEs during the on-therapy period of both studies combined were: somnolence, nausea, headache, and abdominal pain upper, reported by 6 (30.0%), 4 (20.0%), 3 (15.0%) and 3 (15.0%) of subjects, respectively. In addition, for child and adolescent subjects in the combined study population, post-baseline suicidal ideation occurred in 3 adolescents, as assessed via the Columbia Suicide Severity Rating Scale (C-SSRS). Suicidal ideation was reported in 1 adolescent subject who did not report suicidal ideation at the baseline C-SSRS assessment (the baseline C-SSRS assessment was the screening visit of the pharmacokinetic study) (see **WARNINGS AND PRECAUTIONS**, Potential Association with Behavioural and Emotional Changes, Including Self-Harm).

### **Geriatrics:**

In a trial of healthy subjects administered doses of up to 300 mg, there was an approximate 32% increase in  $C_{max}$  and a 55% increase in AUC in subjects older than 75 years of age (n = 17), compared with subjects 18 to 45 years of age (n = 16). Subjects 65 to 75 years of age (n = 15) had no change in  $C_{max}$  but an approximately 32% increase in AUC, compared to subjects 18 to 45 years of age. No dosage adjustment is required solely on the basis of age; however, possible reduced renal clearance of desvenlafaxine should be considered when determining dose.

### **Race:**

Pharmacokinetic analysis on the basis of race (White, N = 466; Black, N = 97; Hispanic, N = 39;

Other, N =33) did not demonstrate an effect on the pharmacokinetics of desvenlafaxine extended-release tablets. No adjustment of dosage on the basis of race is needed.

### **Hepatic Insufficiency:**

The disposition of desvenlafaxine succinate after administration of 100 mg was studied in subjects with mild (Child-Pugh A, n = 8), moderate (Child-Pugh B, n = 8), and severe (Child-Pugh C, n = 8) hepatic impairment and to healthy subjects (n = 12). Average AUC was increased by approximately 31% and 35% in patients with moderate and severe hepatic impairment, respectively, as compared to healthy subjects. Average AUC values were similar in subjects with mild hepatic impairment and healthy subjects (<5% difference). Systemic clearance (CL/F) was decreased by approximately 20% and 36% in patients with moderate and severe hepatic impairment, respectively, as compared to healthy subjects. CL/F values were comparable in mild hepatic impairment and healthy subjects (<5% difference).

The mean  $t_{1/2}$  changed from approximately 10 hours in healthy subjects and subjects with mild hepatic impairment to 13 and 14 hours in moderate and severe hepatic impairment, respectively. No dosage adjustment is necessary for patients with hepatic impairment.

### **Renal Insufficiency:**

The disposition of desvenlafaxine after administration of 100 mg was studied in subjects with mild (n = 9), moderate (n = 8), severe (n = 7) and end-stage renal disease (ESRD) requiring dialysis (n = 9) and in healthy, age-matched control subjects (n = 8). Elimination was significantly correlated with creatinine clearance. Increases in AUCs of about 42% in mild renal impairment, about 56% in moderate renal impairment, about 108% in severe renal impairment, and about 116% in ESRD subjects were observed, compared with healthy, age-matched, control subjects.

The mean terminal half-life ( $t_{1/2}$ ) was prolonged from 11.1 hours in the control subjects to approximately 13.5, 15.5, 17.6, and 22.8 hours in mild, moderate, severe renal impairment and ESRD subjects, respectively. Less than 5% of the drug in the body was cleared during a standard 4-hour hemodialysis procedure. Therefore, supplemental doses should not be given to patients after dialysis.

Dosage adjustment is recommended in patients with significant impairment of renal function (see **DOSAGE AND ADMINISTRATION, Patients with severe renal impairment and end-stage renal disease**).

## **STORAGE AND STABILITY**

Store at 15° to 30°C.

## **SPECIAL HANDLING INSTRUCTIONS**

None.

## **DOSAGE FORMS, COMPOSITION AND PACKAGING**

**Taro-Desvenlafaxine** (desvenlafaxine extended-release tablets) contain 50 and 100 mg

desvenlafaxine (free base) as desvenlafaxine succinate monohydrate:

50 mg, light pink, square pyramid coated tablet debossed with “50” on one side;

100 mg, maroon, square pyramid coated tablet debossed with “100” on one side.

Inactive ingredients consist of hypromellose, hydroxyethyl cellulose, ethyl cellulose, microcrystalline cellulose, magnesium stearate, film coating (which consists of polyvinyl alcohol, titanium dioxide, polyethylene glycol, talc, red iron oxide, black iron oxide (50 mg only) and yellow iron oxide (100 mg only).

**Taro-Desvenlafaxine** 50 mg, and 100 mg tablets are available in:

HDPE Bottles of 14 tablets

HDPE Bottles of 30 tablets

HDPE Bottles of 100 tablets

HDPE Bottles of 1000 tablets



## PART II: SCIENTIFIC INFORMATION

### PHARMACEUTICAL INFORMATION


#### Drug Substance

**Common name:** Desvenlafaxine succinate monohydrate (O-Desmethyl venlafaxine succinate monohydrate)

**Chemical name:** 1-[(1RS)-2-(Dimethylamino)-1-(4-hydroxyphenyl)ethyl]cyclohexanol hydrogen butanedioate monohydrate

**Molecular formula and molecular mass:**  $C_{16}H_{25}NO_2 \cdot C_4H_6O_4 \cdot H_2O$ ; 399.48 (succinate salt monohydrate); molecular mass: 399.48 (succinate salt monohydrate); 263.38 (free base)

#### Structural formula:



**Physicochemical properties:** Desvenlafaxine succinate monohydrate is a white to off-white powder that is soluble in water. The solubility of desvenlafaxine succinate monohydrate is pH dependent (solubility increases at lower pH). Its octanol:aqueous system (at pH 7.0) partition coefficient is 0.21.

**pKa values:** 8.34 (dimethylamino group); and 10.11 (phenolic group)

## CLINICAL TRIALS

### Comparative Bioavailability

A single dose (1 x 50 mg) two period, crossover comparative bioequivalence study between Taro-Desvenlafaxine (Taro Pharmaceuticals Inc. Canada) and PRISTIQ (Pfizer Canada Inc.) was conducted in healthy, adult subjects under fasting conditions. Comparative bioavailability data from the 60 subjects that were included in the statistical analysis are presented in the following table:

#### SUMMARY TABLE OF THE COMPARATIVE BIOAVAILABILITY DATA

Desvenlafaxine (1 x 50 mg) Geometric Mean Arithmetic Mean (CV%)				
Parameter	Test <sup>1</sup>	Reference <sup>2</sup>	% Ratio of Geometric Means	Confidence Interval
<b>AUC<sub>T</sub></b> <b>(ng·h/mL)</b>	2487.07 2801.59 (41.5)	2424.23 2757.39 (42.1)	102.6	89.8 - 117.2
<b>AUC<sub>I</sub></b> <b>(ng·h/mL)</b>	2674.04 3030.05 (44.5)	2588.77 2934.82 (42.8)	103.3	90.8 - 117.5
<b>C<sub>max</sub></b> <b>(ng/mL)</b>	139.97 145.42 (23.8)	133.89 139.49 (26.2)	104.5	96.4 - 113.3
<b>T<sub>max</sub><sup>3</sup></b> <b>(h)</b>	5.25 (1.00 – 16.00)	5.00 (1.00-20.00)		
<b>T<sub>1/2</sub><sup>4</sup></b> <b>(h)</b>	9.58 (36.1)	9.20 (18.8)		

<sup>1</sup>Taro-Desvenlafaxine (desvenlafaxine as desvenlafaxine succinate) extended release tablets, 50 mg (Taro Pharmaceuticals Inc. Canada)

<sup>2</sup>PRISTIQ (desvenlafaxine as desvenlafaxine succinate) extended release tablets, 50 mg (Pfizer Canada Inc.)

<sup>3</sup>Expressed as the median (range) only

<sup>4</sup>Expressed as the arithmetic mean (CV%) only

A single dose (1 x 50 mg) two-period, crossover comparative bioequivalence study between Taro-Desvenlafaxine (Taro Pharmaceuticals Inc. Canada) and PRISTIQ (Pfizer Canada Inc.) was conducted in healthy, adult subjects under fed conditions. Comparative bioavailability data from the 60 subjects that were included in the statistical analysis are presented in the following table:

### SUMMARY TABLE OF THE COMPARATIVE BIOAVAILABILITY DATA

Desvenlafaxine (1 x 50 mg) Geometric Mean Arithmetic Mean (CV%)				
Parameter	Test <sup>1</sup>	Reference <sup>2</sup>	% Ratio of Geometric Means	Confidence Interval
<b>AUC<sub>T</sub></b> <b>(ng·h/mL)</b>	4117.76 4218.59 (22.3)	3853.25 4018.63 (24.0)	106.9	99.4 - 114.9
<b>AUC<sub>I</sub></b> <b>(ng·h/mL)</b>	4362.85 4487.58 (24.3)	4126.41 4325.70 (27.0)	105.7	98.4 - 113.6
<b>C<sub>max</sub></b> <b>(ng/mL)</b>	204.23 206.93 (16.6)	187.10 191.70 (19.0)	109.2	103.4 - 115.2
<b>T<sub>max</sub><sup>3</sup></b> <b>(h)</b>	7.50 (3.00-16.00)	7.50 (2.00-16.00)		
<b>T<sub>1/2</sub><sup>4</sup></b> <b>(h)</b>	9.77 (23.6)	10.26 (29.7)		

<sup>1</sup>Taro-Desvenlafaxine (desvenlafaxine as desvenlafaxine succinate) extended release tablets, 50 mg (Taro Pharmaceuticals Inc. Canada)

<sup>2</sup>PRISTIQ (desvenlafaxine as desvenlafaxine succinate) extended release tablets, 50 mg (Pfizer Canada Inc.)

<sup>3</sup>Expressed as the median (range) only

<sup>4</sup>Expressed as the arithmetic mean (CV%) only

A single dose (1 x 100 mg) two-period, crossover comparative bioequivalence study between Taro-Desvenlafaxine (Taro Pharmaceuticals Inc. Canada) and PRISTIQ (Pfizer Canada Inc.) was conducted in healthy, adult subjects under fasting conditions. Comparative bioavailability data from the 60 subjects that were included in the statistical analysis are presented in the following table:

#### SUMMARY TABLE OF THE COMPARATIVE BIOAVAILABILITY DATA

Desvenlafaxine (1 x 100 mg) Geometric Mean Arithmetic Mean (CV%)				
Parameter	Test <sup>1</sup>	Reference <sup>2</sup>	% Ratio of Geometric Means	Confidence Interval
<b>AUC<sub>T</sub></b> <b>(ng·h/mL)</b>	6285.93 6791.20 (34.4)	6187.47 6848.48 (37.9)	101.6	90.5 - 114.0
<b>AUC<sub>I</sub></b> <b>(ng·h/mL)</b>	6771.97 7353.49 (35.8)	6595.40 7337.52 (39.6)	102.7	91.0 - 115.8
<b>C<sub>max</sub></b> <b>(ng/mL)</b>	295.09 308.93 (29.7)	300.57 312.83 (26.6)	98.2	91.7 - 105.1
<b>T<sub>max</sub><sup>3</sup></b> <b>(h)</b>	5.00 (2.00 – 11.00)	5.25 (2.00-20.00)		
<b>T<sub>1/2</sub><sup>4</sup></b> <b>(h)</b>	10.71 (49.8)	9.94 (16.3)		

<sup>1</sup>Taro-Desvenlafaxine (desvenlafaxine as desvenlafaxine succinate) extended release tablets, 100 mg (Taro Pharmaceuticals Inc. Canada)

<sup>2</sup>PRISTIQ (desvenlafaxine as desvenlafaxine succinate) extended release tablets, 100 mg (Pfizer Canada Inc.)

<sup>3</sup>Expressed as the median (range) only

<sup>4</sup>Expressed as the arithmetic mean (CV%) only

A single dose (1 x 100 mg) two-period, crossover comparative bioequivalence study between Taro-Desvenlafaxine (Taro Pharmaceuticals Inc. Canada) and PRISTIQ (Pfizer Canada Inc.) was conducted in healthy, adult subjects under fed conditions. Comparative bioavailability data from the 60 subjects that were included in the statistical analysis are presented in the following table:

#### SUMMARY TABLE OF THE COMPARATIVE BIOAVAILABILITY DATA

Desvenlafaxine (1 x 100 mg) Geometric Mean Arithmetic Mean (CV%)				
Parameter	Test <sup>1</sup>	Reference <sup>2</sup>	% Ratio of Geometric Means	Confidence Interval
<b>AUC<sub>T</sub></b> <b>(ng·h/mL)</b>	7934.87 8168.53 (22.4)	7957.22 8136.76 (21.7)	99.7	94.8 - 104.9
<b>AUC<sub>I</sub></b> <b>(ng·h/mL)</b>	8335.77 8614.80 (24.4)	8379.66 8592.84 (23.1)	99.5	94.5 - 104.8
<b>C<sub>max</sub></b> <b>(ng/mL)</b>	426.26 435.25 (20.6)	413.72 420.46 (19.0)	103.0	98.8 - 107.5
<b>T<sub>max</sub><sup>3</sup></b> <b>(h)</b>	7.50 (4.00-12.00)	8.00 (4.00-16.00)		
<b>T<sub>1/2</sub><sup>4</sup></b> <b>(h)</b>	9.45 (17.6)	9.59 (17.2)		

<sup>1</sup>Taro-Desvenlafaxine (desvenlafaxine as desvenlafaxine succinate) extended release tablets, 100 mg (Taro Pharmaceuticals Inc. Canada)

<sup>2</sup>PRISTIQ (desvenlafaxine as desvenlafaxine succinate) extended release tablets, 100 mg (Pfizer Canada Inc.)

<sup>3</sup>Expressed as the median (range) only

<sup>4</sup>Expressed as the arithmetic mean (CV%) only

The efficacy of desvenlafaxine extended-release tablets for treatment of depression was established in four 8-week, randomized, double-blind, placebo-controlled, fixed-dose studies (at doses of 50 mg/day to 400 mg/day) in adult outpatients who met the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) criteria for major depressive disorder. In the first study, patients received 100 mg (n = 114), 200 mg (n = 116), or 400 mg (n = 113) of desvenlafaxine extended-release tablets once daily, or placebo (n = 118). In a second study, patients received either 200 mg (n = 121) or 400 mg (n = 124) of desvenlafaxine extended-release tablets once daily, or placebo (n = 124). In two additional studies, patients received 50 mg (n = 150 and n = 164) or 100 mg (n = 147 and n = 158) of desvenlafaxine extended-release tablets once daily, or placebo (n = 150 and n = 161).

The primary outcome measure in all studies was change in the 17-item Hamilton Rating Scale for Depression (HAM-D<sub>17</sub>) total score (LOCF Final). The main secondary outcome measure was overall improvement, as measured by the Clinical Global Impressions Scale - Improvement (CGI-I) (LOCF Final). Other secondary outcome measures included change in HAM-D<sub>17</sub> total score (Observed Case and MMRM) and CGI-I (Observed Case) at week 8, as well as change in the Montgomery Asberg Depression Rating Scale (MADRS) score, change in the Sheehan Disability Scale (SDS) score, and the percentage of CGI-I responders, HAM-D<sub>17</sub> responders, and HAM-D<sub>17</sub> remissions. CGI-I responder was defined as a score of 1 (very much improved) or 2 (much improved), HAM-D<sub>17</sub> responder was defined as  $\geq 50\%$  decrease from baseline HAM-D<sub>17</sub> total score, and remission was defined as HAM-D<sub>17</sub>  $\leq 7$ .

In these studies, the efficacy of desvenlafaxine extended-release tablets for treatment of depression was demonstrated by its superiority over placebo as measured by improvement on the primary outcome measure (HAM-D<sub>17</sub>) total score (LOCF) and the main secondary outcome measure (CGI-I) (LOCF). The results on the other secondary outcome measures were supportive of the positive primary and main secondary outcomes.

In studies directly comparing desvenlafaxine extended-release tablet doses of 50 mg/day and 100 mg/day, there was no suggestion of greater efficacy with the higher dose. Similarly, in studies directly comparing desvenlafaxine extended-release tablet doses of 100 mg/day and 200 mg/day or 400 mg/day there was no suggestion of a greater efficacy with the higher doses [see **DOSAGE AND ADMINISTRATION**]. In contrast adverse events and discontinuations tended to be more frequent at higher doses (see Tables 1 through 5), although no severe toxicity was observed.

### ***Long-Term Maintenance of Effect Studies***

The efficacy of desvenlafaxine extended-release tablets in maintaining antidepressant effect was assessed in a long-term study.

In the long-term trial, adult outpatients meeting DSM-IV criteria for major depressive disorder, who responded to 8 weeks of open-label acute treatment with 50 mg/day desvenlafaxine extended-release tablets and subsequently remained stable for 12 weeks on desvenlafaxine extended-release tablets, were assigned randomly in a double-blind manner to remain on active treatment or switched to placebo for up to 26 weeks of observation for relapse. Response during the open phase was defined as a HAM-D<sub>17</sub> total score of  $\leq 11$  and CGI-I  $\leq 2$  at the day 56 evaluation; stability was defined as not having a HAM-D<sub>17</sub> total score of  $\geq 16$  at any office visit. Relapse during the double-blind phase was defined as follows: (1) a HAM-D<sub>17</sub> total score of  $\geq 16$  at any office visit; (2) discontinuation for unsatisfactory efficacy response; (3) hospitalized for depression; (4) suicide attempt; or (5) suicide.

Patients receiving continued desvenlafaxine extended-release tablet treatment experienced statistically significantly longer time to relapse compared with placebo. At 26 weeks, the Kaplan-Meier estimated probability of relapse was 14% with desvenlafaxine extended-release tablet treatment versus 30% with placebo.

Secondary efficacy measures that supported the primary outcome included: HAM-D<sub>17</sub> total score, remission based on HAM-D<sub>17</sub>, HAM-D<sub>6</sub>, and CGI-S scores.

## **DETAILED PHARMACOLOGY**

### **Clinical Pharmacology**

#### **Overview**

The clearance of desvenlafaxine is uncomplicated, with glucuronidation and renal excretion of desvenlafaxine and its glucuronide being the major routes of elimination.

In vitro and in vivo studies suggest that there is low potential for clinically relevant pharmacokinetic interactions between desvenlafaxine and other prescribed medications. There was an increase in exposure in severe renally impaired patients.

#### **Pharmacokinetic Profile**

The pharmacokinetic profile of desvenlafaxine has been investigated in 23 phase 1 studies enrolling more than 652 healthy subjects and patients with hepatic or renal impairment. Peak plasma concentrations are observed 6 to 10 hours after oral administration. Meals did not affect the bioavailability of desvenlafaxine. The plasma protein binding of desvenlafaxine in humans is low (approximately 30 %) and independent of drug concentration.

The clearance of desvenlafaxine is uncomplicated, with glucuronidation and renal excretion of desvenlafaxine (~45%) and its glucuronide metabolite (~19%) being the major routes of elimination. All metabolites of desvenlafaxine are accounted for in plasma and urine and are inactive. Only minor metabolism occurs through CYP3A4, and in vitro studies show no evidence for induction of the CYP3A4 enzyme pathway.

A study has been conducted to evaluate the effects of single doses of desvenlafaxine extended-release tablets and venlafaxine extended-release (ER) in subjects who had a genotype consistent with an extensive metabolizer (EM) or poor metabolizer (PM) CYP2D6 phenotype. There is no evidence to indicate that CYP2D6 isozymes contribute to the metabolism of desvenlafaxine, however, the metabolism of venlafaxine to desvenlafaxine is dependent on CYP2D6. Therefore, the metabolizer phenotype was expected to influence the pharmacokinetics of venlafaxine but not of desvenlafaxine. After administration of venlafaxine ER, significant differences were observed between EM and PM subjects in the pharmacokinetics of both venlafaxine and desvenlafaxine, resulting in much higher concentrations of venlafaxine and lower concentrations of desvenlafaxine in PM subjects compared with EM subjects. As expected, the CYP2D6 phenotype does not significantly alter the pharmacokinetics of desvenlafaxine after administration of desvenlafaxine extended-release tablets.

#### *Hepatic and Renal Studies*

In keeping with the predominant role of renal excretion, glomerular filtration as measured by

creatinine clearance is the major determinant of desvenlafaxine clearance. Increases in exposure to desvenlafaxine are observed as the degree of renal impairment increased in mild, moderate, and severe renal impairment, and end stage renal disease (ESRD). Changes in the pharmacokinetics of desvenlafaxine with increasing age are also largely due to decreasing renal function. As shown by minimal recovery of desvenlafaxine in dialysate fluid (<5% of administered dose of desvenlafaxine extended-release tablets), dialysis is not expected to have any impact on the pharmacokinetics of desvenlafaxine.

For subjects with mild, moderate, and severe hepatic impairment, as characterized by Child-Pugh A, B, and C categories (see **ACTION AND CLINICAL PHARMACOLOGY, Hepatic Insufficiency**), there was a trend for increased exposures as measured by area under the concentration-versus-time curve (AUC) and  $C_{max}$ . Therefore, although hepatic metabolism is not the most important mechanism for removal of desvenlafaxine, as shown by decreased clearance in moderate and severe hepatic impairment, hepatic metabolism still plays an important role in elimination of desvenlafaxine.

Minor increases in  $C_{max}$  and AUC were observed for women compared with men. Differences in pharmacokinetics due to race were not observed; the metabolism of desvenlafaxine does not utilize enzyme systems that are sensitive to polymorphic distributions in humans.

#### *Drug Interactions*

Based on in vitro data, drugs that inhibit CYP isozymes 1A1, 1A2, 2A6, 2D6, 2C8, 2C9, 2C19, and 2E1 are not expected to have significant impact on the pharmacokinetic profile of desvenlafaxine. Results of additional in vitro studies showed that desvenlafaxine does not inhibit CYP1A2, 2A6, 2C8, 2C9, 2C19 and CYP3A4 isozymes and would not be expected to affect the pharmacokinetics of drugs that are metabolized by these CYP isozymes.

Several drug interaction studies were performed with desvenlafaxine. Observed changes in desipramine pharmacokinetics (increases in AUC and  $C_{max}$ ), when desvenlafaxine extended-release tablets are administered concomitantly, indicate that desvenlafaxine is a weak inhibitor of the CYP2D6 isozyme. Coadministration of midazolam and desvenlafaxine extended-release tablets showed a minor decrease in the relative bioavailability of midazolam. In vitro studies ruled out that induction of CYP3A4 isozyme by desvenlafaxine was responsible for the observed changes. Finally, minor increases in desvenlafaxine exposure during concomitant administration with ketoconazole (a CYP3A4 inhibitor) predict that inhibition of the CYP3A4 metabolic pathway by other drugs would have a minor impact on the pharmacokinetics of desvenlafaxine. The combination of linear pharmacokinetics, a simple metabolic profile without the potential for CYP polymorphism factors, weak interactions with selected probe substrates, and low protein binding results in a low potential for the interaction of desvenlafaxine with other prescribed medications.

#### *Population Pharmacokinetics*

Population pharmacokinetic analyses were conducted to examine factors appropriate to the patient population. The results demonstrated that no dose adjustments are needed for patients receiving treatment with desvenlafaxine extended-release tablets based on the patient demographic characteristics (body weight, age, gender, and race) and concomitant medications taken.



## Safety and Tolerability

Based on data from a thorough QT/QTc study, desvenlafaxine has a low potential to prolong QT interval.

**Table 9: Estimated and 90% Confidence Interval for QTc Changes from Time-Matched Baseline Relative to Placebo at Hour 8 after Dose with Different Heart Rate Corrections<sup>a</sup>**

Treatment	Fridericia's QT Correction (ms)	Population QT Correction (ms)
Desvenlafaxine extended-release tablets 200 mg <sup>b</sup>	1.5 (-0.88, 3.88)	3.18 (0.87, 5.50)
Desvenlafaxine extended-release tablets 600 mg <sup>b</sup>	-2.43 (-4.90, 0.04)	0.98 (-1.42, 3.38)
Moxifloxacin 400 mg (Active control)	10.80 (8.44, 13.16)	10.92 (8.62, 13.22)

a. Mean (90% confidence interval)

b. The Desvenlafaxine extended-release tablets doses of 200 and 600 mg were 2 and 6 times the maximum recommended dose, respectively.

## Nonclinical Pharmacology

Desvenlafaxine succinate salt (DVS) has been developed as a sustained-release (SR) tablet for the treatment of major depressive disorder (MDD). It is a selective inhibitor of the human serotonin and norepinephrine monoamine transporters and is commonly referred to as an SNRI. Nonclinical studies have demonstrated that DVS acutely and dose-dependently increases serotonin (5-HT) and norepinephrine (NE) in the brain frontal cortex.

The nonclinical data indicate that DVS has a profile of in vitro and in vivo activities that demonstrate increases in 5-HT and NE levels that lead to efficacy in models of depression, anxiety and pain. The efficacy of DVS in models of depression is believed to be related to the potentiation of serotonergic and noradrenergic activity in the central nervous system (CNS). Characterization of DVS was done using in vitro assays to determine selectivity for the 5-HT and NE monoamine transporters. Desvenlafaxine was profiled at 10 µM for activity at 96 targets (i.e., receptors, transporters, enzymes, channels) by NovaScreen<sup>®</sup>. No significant activity was detected for any targets with the exception of the 5-HT and NE monoamine transporters. Desvenlafaxine, by inhibiting the 5-HT and NE transporter, elevates rat cortical and hypothalamic levels of both 5-HT and NE, as measured using microdialysis techniques. These increased 5-HT and NE levels are also evident by the acute decreases observed in serotonergic and noradrenergic neuronal firing in rats that is due to stimulation of inhibitory cell body auto receptors by 5-HT and NE, respectively. Desvenlafaxine produces a desensitization of rat pineal beta-mediated cAMP response due to the increase in NE caused by NE transporter blockage.

Desvenlafaxine was active in the 4-plate test paradigm in mice supporting anxiolytic activity and was active in several rodent models of depression. DVS was efficacious in rodent pain models, indicating antinociceptive activity.

Safety pharmacology studies conducted under the DVS SR development program, consisted of the core battery of safety pharmacology studies to evaluate the effects of a single oral dose on the CNS and respiratory system of rats and the cardiovascular system of dogs, as well as in vitro human ether a-go-go related gene (hERG) channel assays. Earlier studies, not conducted under Good Laboratory Practice (GLP) consisted of safety pharmacology studies on cardiovascular effects in dogs (in vitro Purkinje fiber electrophysiology and in vivo intracardiac conduction) and ancillary pharmacology studies on the effects on the CNS of mice and rats after a single intraperitoneal (IP) dose, on the respiratory system of guinea pigs after an intravenous (IV) dose, and in rats on the renal/urinary system, the gastrointestinal system, and glucose metabolism after a single oral dose.

In safety pharmacology studies in rats given a single oral gavage dosage of DVS at up to 1000 mg/kg, there were no toxicologically significant effects of desvenlafaxine on the CNS or respiratory system. While there was a dose-related decrease in respiratory rate, the mean values remained within published normal limits for rats.

Results of in vitro studies (hERG assays with DVS at concentrations up to 195  $\mu\text{M}$  and its metabolite N,O-didesmethylvenlafaxine at a concentration of 10  $\mu\text{M}$ , and a canine Purkinje fiber assay with desvenlafaxine fumarate salt at 10  $\mu\text{M}$ ) and an in vivo study (intracardiac conduction in dogs given desvenlafaxine butenedioate salt as a single IV dosage at up to 10 mg/kg) indicated that desvenlafaxine does not produce any effects on atrial or ventricular conduction, including conduction through the specialized ventricular conduction system or blockade of cardiac ion channels. In cardiovascular safety pharmacology studies, there were no effects on the electrocardiogram (ECG), including PR, QRS, and QTc intervals, of dogs given a single oral gavage dosage of DVS at up to 300 mg/kg or DVS SR tablets at 100 mg/kg. There were increases in the heart rate (HR) and mean arterial blood pressure (MABP) of dogs given DVS (100 and 300 mg/kg) or DVS SR tablets (100 mg/kg), and increases in the MABP of spontaneously hypertensive rats given a single oral dosage of desvenlafaxine free base (50 mg/kg); these changes were consistent with similar effects reported for some antidepressant agents in humans. In addition, in oral repeat-dose toxicity studies, there were no compound-related changes in the ECG, or macroscopic or microscopic changes in the hearts of dogs given desvenlafaxine free base at dosages up to 300 mg/kg for 3 months, DVS at dosages up to 50 mg/kg/day for 9 months or 100 mg/kg/day for 3 months, or DVS SR tablets at up to 400 mg/kg/day for 3 months.

In rats given a single oral dosage up to 30 mg/kg/day, desvenlafaxine produced no adverse effect on renal excretory function, no effect on gastric acid secretion or emptying, and no irritation to the gastrointestinal system. Desvenlafaxine had no effect on plasma glucose levels in fed or fasted rats after a single oral dosage of 30 mg/kg; however, in a glucose tolerance test in fasted rats, the peak plasma glucose level was significantly decreased at 30 mg/kg.

## **TOXICOLOGY**

### **Toxicology Program**

The principal toxicology studies included single-dose and repeat-dose studies in rats and dogs; genetic toxicology studies; 2-year carcinogenicity studies in mice and rats; and reproductive and developmental studies in rats and rabbits. Special studies were conducted to define target organ toxicity, to evaluate the gastrointestinal tolerability of the sustained release (SR) tablets that were used in clinical trials, and to further evaluate the effects of desvenlafaxine on fertility in male and

female rats.

### **Single-Dose**

A single oral dosage of desvenlafaxine (salt form) resulted in death at  $\geq 1800$  mg/kg in mice and  $\geq 2500$  mg/kg in rats. A single IP dosage of desvenlafaxine (salt form) resulted in death at  $\geq 250$  mg/kg in mice. A single IP dosage of DVS resulted in death at  $\geq 700$  mg/kg in rats. There was no mortality in dogs given a single oral dosage of desvenlafaxine (salt form) at up to 500 mg/kg.

### **Repeat-Dose**

#### *Rats*

In the 1-month toxicity study in rats, the no-observed-adverse-effect level (NOAEL) was 675 mg/kg/day (the highest dosage), based on no toxicologically significant effects at any dosage. In the 3-month toxicity study in rats, the NOAEL was 100 mg/kg/day, based on mortality and decreased food consumption at 1000 mg/kg/day, and increased salivation and decreased body weights and body-weight gains at  $\geq 500$  mg/kg/day. In the 6-month toxicity study in rats, the NOAEL was 100 mg/kg/day in males (based on decreases in body weight in males at 300 mg/kg/day) and 300 mg/kg/day in females (the highest dosage administered).

#### *Dogs*

In the 1-month toxicity study in dogs, the NOAEL was 175 mg/kg/day (the highest dosage), based on no toxicologically significant effects at any dosage. In the 3-month toxicity study in dogs, the NOAEL was 100 mg/kg/day, based on mortality and decreased body weights at 300 mg/kg/day and central nervous system (CNS)-related clinical observations (chorea-like movements, stereotypy, and convulsions as early as week 1) at 200 and 300 mg/kg/day. Because the target organ toxicity was not identified in this 3-month study, two (2) additional 3-month studies were conducted at higher dosages (oral gavage, up to 500 mg/kg/day; SR tablets up to 400 mg/kg/day). These 2 additional 3-month studies demonstrated the CNS to be the target organ based on clinical signs and the NOAEL was 100 mg/kg/day and 200 mg/kg/day in the oral gavage and SR tablet studies, respectively. In the 9-month toxicity study in dogs, the NOAEL was 50 mg/kg/day (the highest dosage), based on no adverse effects at any dosage.

### **Carcinogenesis**

Desvenlafaxine succinate administered by oral gavage to mice and rats for 2 years did not increase the incidence of tumors in either study.

#### *Mice*

Mice received desvenlafaxine at dosages up to 500/300 mg/kg/day (dosage lowered after 45 weeks of dosing). The 300 mg/kg/day dose was 180 times on an mg/kg basis, the maximum recommended human dose (MRHD) of 100 mg/day, and 15 times the MRHD on a mg/m<sup>2</sup> basis.

#### *Rats*

Rats received desvenlafaxine at dosages up to 300 mg/kg/day (males) or 500 mg/kg/day (females). The highest dose was 180 (males) or 300 (females) times, on a mg/kg basis the MRHD of 100 mg/day, and 29 (males) or 48 (females) times the MRHD of 100 mg/day, on a mg/m<sup>2</sup> basis.

## **Mutagenesis**

Desvenlafaxine was not genotoxic in the in vitro bacterial mutation assay (Ames test) and was not clastogenic in an in vitro chromosome aberration assay in cultured CHO cells, an in vivo mouse micronucleus assay, or an in vivo chromosome aberration assay in rats. Additionally, desvenlafaxine was not genotoxic in the in vitro CHO mammalian cell forward mutation assay and was negative in the in vitro BALB/c-3T3 mouse embryo cell transformation assay.

## **Impairment of Fertility**

Reduced fertility was observed in a study in which both male and female rats received desvenlafaxine. This effect was noted at oral doses approximately 60 times, on a mg/kg basis, and 10 times the maximum human dose (MRHD) of 100 mg/day on a mg/m<sup>2</sup> basis. There was no effect on fertility at oral doses approximately 18 times the MRHD on a mg/kg basis and 3 times the MRHD on a mg/m<sup>2</sup> basis. The human relevance of this finding is unknown.

## **Teratogenicity**

When desvenlafaxine was administered orally to pregnant rats and rabbits during the period of organogenesis, there was no evidence of teratogenicity in rats at any doses tested, up to 60 times on a mg/kg basis and up to 10 times the maximum recommended human dose (MRHD) of 100 mg/day (on a mg/m<sup>2</sup> basis) in rats. In rabbits, there was no evidence of teratogenicity at doses up to 45 times (on a mg/kg basis) the MRHD of 100 mg/day, or 15 times the MRHD (on a mg/m<sup>2</sup> basis). However, fetal weights were decreased in rats with a no effect dose 60 times the MRHD (on a mg/kg basis) and 10 times the MRHD (on a mg/m<sup>2</sup> basis).

## **Reproductive Toxicology**

When administered orally to pregnant rats throughout gestation and lactation and continued through weaning, desvenlafaxine has been shown to cause decrease in fetal weights, decrease in pup weights and increase in pup deaths when given in doses 180 times the human dose of 100 mg/day on a mg/kg basis, and 29 times on a mg/m<sup>2</sup> basis. Post-weaning growth and reproductive performance of the progeny were not affected by maternal treatment with desvenlafaxine.

## **Juvenile Animal Studies**

In a juvenile animal study, male and female rats were treated with desvenlafaxine (75, 225 and 675 mg/kg/day) starting on postnatal day (PND) 22 through 112. Behavioral deficits (longer time immobile in a motor activity test, longer time swimming in a straight channel test, and lack of habituation in an acoustic startle test) were observed in males and females but were reversed after a recovery period. A No Adverse Effect Level (NOAEL) was not identified for these deficits. The Low Adverse Effect Level (LOAEL) was 75 mg/kg/day which was associated with plasma exposure (AUC) twice the levels measured with a pediatric dose of 100 mg/day. In a second juvenile animal study, male and female rats were administered desvenlafaxine (75, 225 or 675 mg/kg/day) for 8-9 weeks starting on PND 22 and were mated with naïve counterparts. Delays in sexual maturation and decreased fertility, number of implantation sites and total live embryos were observed in treated females at all doses. The LOAEL for these findings is 75 mg/kg/day which was associated with an

AUC twice the levels measured with a pediatric dose of 100 mg/day. These findings were reversed at the end of a 4-week recovery period. The relevance of these findings to humans is not known.

## REFERENCES

1. Akiskal HS, Benazzi F, Perugi G, Rihmer Z. Agitated "unipolar" depression re-conceptualized as a depressive mixed state: Implications for the antidepressant-suicide controversy. *J Affect Disord.* 2005; 85:245-58.
2. Boyer EW, Shannon M. The Serotonin Syndrome. *N Engl J Med.* 2005; 352:1112-20.
3. Boyer P, Montgomery S, Lepola U, Germain JM, Brisard C, Ganguly R. et al. Efficacy, safety, and tolerability of fixed-dose desvenlafaxine 50 and 100 mg/day for major depressive disorder in a placebo-controlled trial. *Int. Clin. Psychopharmacology* 2008; 23(5): 243-253.
4. Culpepper L, Davidson JRT, Dietrich AJ, Goodman WK, Kroenke K, Schwenk TL. Suicidality as a Possible Side Effect of Antidepressant Treatment. *J Clin Psychiatry.* 2004; 6(2):78-88.
5. DeMartinis NA, Yeung PP, Entsuah R, Manley AL. A Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Desvenlafaxine Succinate in the treatment of Major Depressive Disorder. *J Clin Psychiatry* 2007; 68 (5): 677-688.
6. Haddad PM. Antidepressant discontinuation syndromes. *Drug Saf.* 2001; 24(3):183-97.
7. Illett KF, Hackett LP, Dusci LJ, Roberts MJ, Kristensen JH, Paech J, et al. Distribution and excretion of venlafaxine and O-desmethylvenlafaxine in human milk. *Br J Clin Pharmacol.* 1998; 45:459-62.
8. Liebowitz MR, Manley AL, Padmanabhan SK, Ganguly R, Tummala R, Tourian KA. Efficacy, safety, and tolerability of desvenlafaxine 50 mg/day and 100 mg/day in outpatients with major depressive disorder. *Curr Med Res and Opin* 2008; 24(7): 1877-1890
9. Millan MJ. The role of monoamines in the actions of established and novel antidepressant agents: a critical review. *Eur J Pharmacol.* 2004; 500:371-84.
10. Rosenthal JZ, Boyer P, Vialet C, Hwang E, Tourian K. Efficacy and safety of desvenlafaxine 50 mg/d for prevention of relapse in major depressive disorder: A randomized controlled trial. *J Clin Psychiatry.* 2013; 74:2.
11. Pfizer Canada Inc., Pristiq® Product Monograph, Control No. 225933, Date of Revision: February 05, 2020.

## PART III: CONSUMER INFORMATION

**PrTaro-Desvenlafaxine**  
**desvenlafaxine extended-release tablets**  
**50 and 100 mg**  
**desvenlafaxine, as desvenlafaxine succinate**  
**monohydrate**

This leaflet is part III of a three-part “Product Monograph” published when Taro-Desvenlafaxine was approved for sale in Canada and is designed specifically for Consumers. This leaflet is a summary and will not tell you everything about Taro-Desvenlafaxine. For further information or advice, please see your doctor or pharmacist.

### ABOUT THIS MEDICATION

#### What the medication is used for:

Taro-Desvenlafaxine has been prescribed to you by your doctor to treat your depression. Treatment with these types of medications is most safe and effective when you and your doctor have good communication about how you are feeling.

#### What it does:

Taro-Desvenlafaxine belongs to a class of medicines called serotonin and norepinephrine reuptake inhibitors (SNRIs). It is thought to work by affecting two naturally occurring brain chemicals, serotonin and norepinephrine.

#### When it should not be used:

Do not use Taro-Desvenlafaxine if you are:

- allergic (hypersensitive) to desvenlafaxine, venlafaxine or any of the other ingredients in Taro-Desvenlafaxine.
- taking or have taken, within the last 14 days, another medicine known as monoamine oxidase inhibitor (MAOI) including linezolid, an antibiotic, and methylene blue, a dye used in certain surgeries. Taking an MAOI together with many prescription medicines including Taro-Desvenlafaxine can cause serious or even life-threatening side effects. Also, you must wait at least 7 days after you stop taking Taro-Desvenlafaxine before you take any MAOI. (See Other Medicines and Nutritional or Herbal Supplements.)
- taking other drugs that contain venlafaxine or desvenlafaxine.
- taking any prescription or non-prescription medicines, including nutritional or herbal supplements without checking with your doctor first (see Serotonin syndrome or NMS-like reactions).

#### What the medicinal ingredient is:

O-Desmethyl venlafaxine succinate monohydrate

#### What the nonmedicinal ingredients are:

The non-medicinal ingredients are:

hypromellose, hydroxyethyl cellulose, ethyl cellulose, microcrystalline cellulose, magnesium stearate, film coating (which consists of polyvinyl alcohol, titanium dioxide, polyethylene glycol, talc, red iron oxide, black iron oxide (50 mg only), yellow iron oxide (100 mg only)).

#### What dosage form it comes in:

- The 50 mg tablet is a light pink, square pyramid shaped coated tablet debossed with “50” on one side (76 mg desvenlafaxine succinate monohydrate equivalent to 50 mg desvenlafaxine).
- The 100 mg tablet is a maroon, square pyramid coated tablet debossed with “100” on one side (152 mg desvenlafaxine succinate monohydrate equivalent to 100 mg desvenlafaxine).

Taro-Desvenlafaxine 50 mg and 100 mg are available in:

- HDPE Bottles of 14 tablets
- HDPE Bottles of 30 tablets
- HDPE Bottles of 100 tablets
- HDPE Bottles of 1000 tablets.

### WARNINGS AND PRECAUTIONS

#### New or Worsened Emotional or Behavioural Problems

Particularly in the first few weeks or when doses are adjusted, a small number of patients taking drugs of this type may feel worse instead of better. They may experience new or worsened feelings of aggression, agitation, hostility, anxiety, impulsivity, or thoughts about suicide, self-harm or harm to others. Suicidal thoughts and actions can occur in any age group but may be more likely in patients 18 to 24 years old. Should this happen to you or those in your care, **consult your doctor immediately**. Close observation by a doctor is necessary in this situation. **Do not discontinue your medication on your own.**

You may be more likely to think like this if you have previously had thoughts about harming yourself.

You may find it helpful to tell a relative or close friend that you are depressed and ask them to read this leaflet. You might ask them to tell you if they think your depression or anxiety is getting worse, or if they are worried about changes in your behaviour.

Taking **Taro-Desvenlafaxine** may increase your risk of experiencing sexual problems, which may continue after **Taro-Desvenlafaxine** has been discontinued. Tell your doctor if you experience symptoms such as sexual dysfunction, ejaculation disorder (in men), ejaculation failure (in men), libido decrease or anorgasmia (difficulty reaching orgasm).

#### **Not for use in Children**

**Taro-Desvenlafaxine** should not be used for children and adolescents under 18 years of age.

#### **Bone Fracture Risk**

Taking **Taro-Desvenlafaxine** may increase your risk of breaking a bone if you are elderly or have osteoporosis or have other major risk factors for breaking a bone. You should take extra care to avoid falls especially if you get dizzy or have low blood pressure.

#### **Other Medicines and Nutritional or Herbal Supplements**

- Please tell your doctor or pharmacist if you are taking or have recently taken any other medicines, including medicines obtained without a prescription.
- Avoid taking **Taro-Desvenlafaxine** with other medicines containing venlafaxine or desvenlafaxine.
- Your health professional will decide if you can take **Taro-Desvenlafaxine** with other medicines.

#### **Angle-closure Glaucoma**

**Taro-Desvenlafaxine** can cause an acute attack of glaucoma. Having your eye examined before you take **Taro-Desvenlafaxine** could help identify if you are at risk of having angle-closure glaucoma. Seek immediate medical attention if you experience:

- eye pain
- changes in vision
- swelling or redness in or around the eye

#### **Other Medical Problems**

**Before you use Taro-Desvenlafaxine, tell your doctor or pharmacist if you:**

- are taking other medicines, herbal or nutritional supplements (see Other Medicines and Nutritional or Herbal Supplements and Serotonin syndrome).
- have a history of high blood pressure.
- have a history of heart problems.
- have a narrowing or blockage of your gastrointestinal tract (your oesophagus, stomach, or small or large intestine).
- have a history of fits (seizures).
- have a history of low sodium levels in your blood.
- have a bleeding disorder or have been told that you have low platelets.
- had a recent bone fracture or were told you have

osteoporosis or risk factors for osteoporosis.

- have a history of high cholesterol.
- have a history or family history of mania or bipolar disorder.
- have kidney problems.
- are pregnant or thinking about becoming pregnant, or if you are breast feeding.

If any of these conditions apply to you, please talk with your doctor before taking **Taro-Desvenlafaxine**.

### **INTERACTIONS WITH THIS MEDICATION**

**Do not use Taro-Desvenlafaxine if you are taking or have recently taken monoamine oxidase inhibitors.**

Certain laboratory results may be affected by use of **Taro-Desvenlafaxine**, discuss with your doctor if you receive any unusual lab reports.

You should tell your doctor if you are taking or have recently taken any medications (prescription, nonprescription, or natural/herbal), especially:

- Monoamine oxidase inhibitors (MAOI) including linezolid, an antibiotic, and methylene blue, a dye used in certain surgeries. Do not take **Taro-Desvenlafaxine** with an MAOI or within 14 days of stopping an MAOI. Taking an MAOI together with many prescription medicines, including **Taro-Desvenlafaxine**, can cause serious or even life-threatening side effects. Also, you need to wait at least 7 days after you stop taking **Taro-Desvenlafaxine** before you take an MAOI.
- Certain medicines which may affect blood clotting and increase bleeding, such as oral anticoagulants (e.g. warfarin, dabigatran), acetylsalicylic acid (e.g. Aspirin) and other non-steroidal anti-inflammatory drugs (e.g. ibuprofen).
- Medicines containing venlafaxine or other medicines containing desvenlafaxine.
- **Serotonin syndrome or a neuroleptic malignant syndrome (NMS)-like reactions:** Rare, but potentially life-threatening conditions called serotonin syndrome or NMS-like reactions can cause serious changes in how your brain, muscles and digestive system work and can happen when medicines like **Taro-Desvenlafaxine** are taken, particularly when taken with certain other medications such as:



- medicines to treat migraine headaches known as triptans
- medicines used to treat mood or thought disorders, including tricyclics, lithium, selective serotonin reuptake inhibitors (SSRIs); or serotonin norepinephrine reuptake inhibitors (SNRIs), or dopamine antagonists, including antipsychotics
- amphetamines
- sibutramine
- certain medicines used to treat pain, such as fentanyl (used in anaesthesia or to treat chronic pain), tramadol, tapentadol, meperidine, methadone, pentazocine
- certain medicines used to treat cough, such as dextromethorphan
- St. John's Wort
- MAOIs (including linezolid, an antibiotic and methylene blue, a dye sometimes injected before surgery to guide the surgeon)
- tryptophan supplements

Before you take **Taro-Desvenlafaxine** and any of these medicines together, talk to your healthcare professional about the possibility of serotonin syndrome NMS-like reactions.

Signs and symptoms of serotonin syndrome or NMS may include a combination of the following:

Agitation (excitability, restlessness), hallucinations, confusion, loss of coordination, muscle twitching or stiffness, fast heartbeat, increased body temperature, fast changes in blood pressure, overactive reflexes, diarrhea, coma, nausea, vomiting.

Get medical care right away if you think serotonin syndrome is happening to you.

**Central Nervous System drugs:** caution is advised when **Taro-Desvenlafaxine** is taken in combination with other centrally acting drugs or substances, including alcohol and sedative drugs (benzodiazepines, opiates, antipsychotics, phenobarbital, sedative antihistamines). Inform your doctor if you are taking any of these drugs.

You should avoid alcohol while taking **Taro-Desvenlafaxine**.

#### **Switching from other antidepressants**

Side effects from discontinuing antidepressant medication have occurred when patients switched from other antidepressants, including venlafaxine, to **Taro-Desvenlafaxine**. Your doctor may gradually reduce the dose of your initial antidepressant medication to help to reduce these side effects.

## **PROPER USE OF THIS MEDICATION**

Always take **Taro-Desvenlafaxine** exactly as your health professional has told you. You should check with your health professional if you have any questions.

**Taro-Desvenlafaxine** is for oral use.

- **Taro-Desvenlafaxine** should be taken at approximately the same time each day with or without food. Tablets must be swallowed whole with fluid and not divided, crushed, chewed, or dissolved as it is time released.

Do not stop taking **Taro-Desvenlafaxine** without talking to your doctor.

#### **Usual dose:**

The usual dose is 50 mg taken once daily. Your doctor may increase your dose if you need it.

#### **Overdose:**

In case of an overdose, call your health professional and/or poison control centre or go to emergency at a hospital right away. Take your medicines with you to show the doctor.

#### **Missed dose:**

If you miss a dose, take it as soon as you remember. However, if it is almost time for your next dose, skip the missed dose and take only a single dose as usual. Do not take a double dose to make up for a forgotten tablet.

#### **What should you do before stopping Taro-Desvenlafaxine?**

Do not stop taking or change the dose of **Taro-Desvenlafaxine** without first discussing this with your health professional. Your health professional may want to slowly decrease your dose of **Taro-Desvenlafaxine** to help avoid side effects. Some patients, who suddenly stop taking **Taro-Desvenlafaxine** after more than 1 week of therapy, have felt dizzy, sick (nausea), had a headache or experienced irritability, insomnia, diarrhea, anxiety, abnormal dreams, fatigue, sweating. These symptoms are usually not serious and disappear within a few days, but if you have symptoms that are troublesome you should ask your doctor for advice.

#### **Pregnancy and breast-feeding**

The safety of **Taro-Desvenlafaxine** during human pregnancy has not been established. Taking **Taro-Desvenlafaxine** in mid to late pregnancy may increase the risk of preeclampsia (high blood pressure and protein in the urine) and taking it near delivery may increase the risk of heavy bleeding after giving birth. Desvenlafaxine is excreted in

human milk. Tell your doctor immediately if you become pregnant, or if you are trying to become pregnant or are breastfeeding. If you do become pregnant while taking this drug, do not change your dosage without consulting your doctor.

Post marketing reports indicate that some newborns whose mothers took an SNRI (Serotonin Norepinephrine Reuptake Inhibitor), SSRI (Selective Serotonin Reuptake Inhibitor) or other newer antidepressants, during pregnancy have developed complications at birth requiring prolonged hospitalization, breathing support and tube feeding. Reported symptoms include: feeding and/or breathing difficulties, seizures, tense or overly relaxed muscles, jitteriness and constant crying. These symptoms are consistent with either a direct adverse effect of the medication on the baby, or possibly a discontinuation syndrome caused by sudden withdrawal from the drug. These symptoms normally resolve over time. However, if your baby experiences any of these symptoms, contact your doctor as soon as you can.

#### **Driving and using machines**

Do not drive or operate any tools or machines until you know how **Taro-Desvenlafaxine** affects you. Do not drive or operate any tools or machines if **Taro-Desvenlafaxine** affects you in a way that prevents you from safely performing these operations.

If you have any further questions on the use of this product, ask your doctor or pharmacist.

### **SIDE EFFECTS AND WHAT TO DO ABOUT THEM**

Like all medications, **Taro-Desvenlafaxine** can cause some side effects. You may not experience any of them. For most patients these side effects are likely to be minor and temporary. However, some can be serious. Some of these side effects may be dose related. Consult your doctor if you experience these or other side effects, as the dose may need to be adjusted.

If you experience an allergic reaction (including red skin, hives, itching, swelling of the lips, face, tongue, throat, trouble breathing, wheezing, shortness of breath, skin rashes, blisters of the skin, sores or pain in the mouth or eyes) or any severe or unusual side effects, stop taking the drug and seek emergency medical attention immediately.

#### **Frequency of Side Effects**

*Very common* (in more than 1 in 10 patients): Nausea, Dry mouth, Dizziness, Trouble Sleeping, Sweating, Headache, Drowsiness

*Common* (in more than 1 in 100 patients, but in less than 1 in 10 patients): Heart pounding, Heart racing, Ringing in the

ears, Vertigo, Dilated pupils, Vision blurred, Vomiting, Diarrhea, Weakness, Chills, Feeling Jittery, Irritability, Weight Decreased, Weight Increased, Blood Pressure Increased, Musculoskeletal Stiffness, Shaking, Disturbance in Attention, Tingling sensations, Taste changes, No orgasms, Anxiety, Nervousness, Interest in sex decreased, Abnormal dreams, Ejaculation delayed (in men), Erectile dysfunction (in men), Yawning, Rash, Hot flush, Decreased appetite, Constipation, Tiredness, Drug withdrawal syndrome, Liver function tests abnormal

*Uncommon* (in more than 1 in 1000 patients, but in less than 1 in 100 patients): Hypersensitivity, Blood cholesterol increased, Blood prolactin increased, Blood triglyceride increased, Fainting, Depersonalization, Nose bleeds, Drop in blood pressure when standing, Coldness in hands and feet, Loss of hair, orgasm abnormal, Movement disorder, Difficulty emptying your bladder, Urinary hesitation, protein in the urine, Ejaculation disorder (in men), Ejaculation failure (in men), Sexual dysfunction

*Rare* (in more than 1 in 10,000 patients, but in less than 1 in 1000 patients): Seizures, Sodium levels decreased, Swelling beneath the skin (e.g. throat, face, hands), Mania, Hypomania, Convulsions, Hallucinations, Muscle contractions, Sensitivity to light.

#### **Other Side Effect Information**

These are not all the possible side effects of **Taro-Desvenlafaxine**. Call your health professional right away if the side effects become serious, if you notice any side effects not listed in this leaflet, or if there is any other side effect that concerns you.

#### **Discontinuation Symptoms**

Contact your doctor before stopping or reducing your dosage of **Taro-Desvenlafaxine**. Symptoms such as visual impairment, high blood pressure, dizziness, nausea, headache, irritability, trouble sleeping, diarrhea, anxiety, abnormal dreams, tiredness, and sweating have been reported after stopping treatment with **Taro-Desvenlafaxine**. Tell your doctor immediately if you have any of these or other symptoms. Your doctor may adjust the dosage of **Taro-Desvenlafaxine** to alleviate the symptoms.

SERIOUS SIDE EFFECTS, HOW OFTEN THEY HAPPEN AND WHAT TO DO ABOUT THEM				
Symptom/effect		Talk with your doctor or pharmacist right away		Stop taking drug and seek immediate medical help
		Only if severe	In all cases	
Common	High Blood Pressure on 3 occasions		✓	
Common	Increased blood pressure		✓	
Common	Increased Cholesterol		✓	
Uncommon	<b>Allergic reactions:</b> red skin, hives, itching, swelling of the lips, face, tongue, throat, trouble breathing, wheezing, shortness of breath, skin rashes, blisters of the skin, sores or pain in the mouth or eyes			✓
Unknown	Low Platelets: Bruising or unusual bleeding from the skin or other areas		✓	
Rare	<b>Mania / Hypomania:</b> elevated or irritable mood, decreased need for sleep, racing thoughts		✓	
Rare	<b>Seizures:</b> loss of consciousness with uncontrollable shaking; "fit"			✓
Rare	<b>Severe Increased Blood Pressure:</b> headache, stronger and possibly faster heartbeat, chest pain, dizziness, excessive tiredness, and blurred vision			✓
Rare	Uncontrollable movements of the body or face		✓	
Rare	<b>Glaucoma:</b> Swelling or redness in or around the eye, eye pain, and changes in vision			✓
See Warnings and precautions	<b>Low sodium level in blood:</b> tiredness, weakness, confusion combined with achy, stiff or uncoordinated muscles		✓	
See Warnings	New or worsened emotional or		✓	

SERIOUS SIDE EFFECTS, HOW OFTEN THEY HAPPEN AND WHAT TO DO ABOUT THEM				
Symptom/effect		Talk with your doctor or pharmacist right away		Stop taking drug and seek immediate medical help
		Only if severe	In all cases	
and precautions	behavioural problems			
See Warnings and precautions	<b>Serotonin Syndrome:</b> a combination of most or all of the following: confusion, restlessness, sweating, shaking, shivering, high fever, sudden jerking of the muscles, hallucinations, fast heartbeat			✓

*This is not a complete list of side effects. For any unexpected effects while taking Taro-Desvenlafaxine, contact your doctor or pharmacist.*

Keep out of the reach and sight of children.

Store at 15° to 30°C.

Do not use **Taro-Desvenlafaxine** after the expiration date (EXP), which is stated on the package. The expiration date refers to the last day of that month.

Medicines should not be disposed of in wastewater or in household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help to protect the environment.

#### **REPORTING SIDE EFFECTS**

**You can report any suspected side effects associated with the use of health products to Health Canada by:**

- **Visiting the Web page on Adverse Reaction Reporting (<https://www.canada.ca/en/health-canada/services/drugs-health-products/medeffect-canada/adverse-reaction-reporting.html>) for information on how to report online, by mail or by fax; or**
- **Calling toll-free at 1-866-234-2345**

*NOTE: Contact your health professional if you need information about how to manage your side effects. The Canada Vigilance Program does not provide medical advice.*

## **MORE INFORMATION**

This document plus the full product monograph, prepared for health professionals, can be found at: [www.taro.com](http://www.taro.com) or can be obtained by calling : 1-800-268-1975.

This leaflet was prepared by Taro Pharmaceuticals Inc.

Date of Revision: OCT 19, 2022